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ABSTRACT
THE EXPERIENCES AND NEEDS OF INDIVIDUALS WITH A VARIANT OF
UNCERTAIN SIGNIFICANCE (VUS) ON GENETIC TESTS FOR HEREDITARY
CANCER SYNDROMES: A GROUNDED THEORY STUDY
February 2022
DANIELLE GOULD, B.S., UNIVERSITY OF MASSACHUSETTS AMHERST
B.S.N., SALEM STATE UNIVERSITY
M.S.N., UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Professor Memnun Seven
Background: The use of multigene panel testing for identifying individuals with hereditary
cancer susceptibility has expanded in recent years. The number of individuals who have
a variant of unknown significance (VUS) result is increasing. However, little is known
about the experiences and needs of this group. This study’s purpose was to describe the
experiences and needs of individuals with a VUS result by focusing on their experiences
in communicating with healthcare providers and family members.
Methods: A constructivist grounded theory approach was used. Recruitment took place
from January–July 2021 through social media: the Prospective Registry of Multiplex
Testing (PROMPT), and the Facing Our Risk (FORCE) websites. A total of 20
individuals participated in the study. Data were collected through semistructured
interviews, and the verified transcripts were analyzed in NViVo.
Results: Categories were sorted into by time: pretest, testing, and posttesting process.
Categories included motivations, communication with family, family characteristics,
communication with healthcare providers, other factors affecting the testing experiences,
feelings about having a VUS, recall and understanding of the test result and its
implications, coping strategies used, and risk management strategies used. From these
categories, a theoretical model to describe the experiences of individuals with a VUS
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was developed. In the theory, contextual factors such as personality, coping style, and
cancer history, decisions about medical care, communicating with healthcare providers
and family members, and needs such as knowledgeable and trustworthy providers,
support for emotional needs, and open lines of communication were part of the
experience described by participants.
Conclusion: This study describes the experiences of individuals who have a VUS from
their point of view. The proposed theoretical model proposes the key themes that impact
the experience: context; decision-making; communication with healthcare providers and
family; and the need for knowledgeable and trustworthy providers; met emotional needs;
and open lines of communication.

Key words: Grounded theory, VUS, Genetic testing, Patient experience, Cancer,
Hereditary cancer
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CHAPTER 1
INTRODUCTION
Hereditary Cancer Syndromes
Hereditary cancer syndromes are caused by mutations (changes) in certain
genes passed from parents to children. In a hereditary cancer syndrome, certain
patterns of cancer may be seen within families (National Cancer Institute [NCI], 2011).
One of the most recognized is hereditary breast and ovarian cancer (HBOC), which is
caused by pathogenic variants (PVs) on the BRCA1 or BRCA2 genes (Petrucelli et al.,
2016). Lynch syndrome was first recognized in the early 1900s as a familial colon cancer
syndrome and is now linked to PVs on the MLH1, MSH2, MSH6, PMS2, or EPCAM
genes. It has also been linked to multiple other cancers, including ovarian and uterine
among others (Kohlmann & Gruber, 2018). These syndromes are inherited in an
autosomal dominant manner, meaning that only one pathogenic allele is needed to have
the syndrome. However, the penetrance of these syndromes varies based on the type of
pathogenic change that was inherited. Genetic testing for these syndromes has been
increasingly available since the 1990s (Molteni, 2019).
As genetic testing has expanded, multiple other hereditary cancer syndromes
have been identified. Hereditary risks for breast cancer are now linked to the ATM,
PALB2, PTEN, and CDH1 (Kaurah & Huntsman, 2018; Petrucelli et al., 2016). Familial
adenomatous polyposis (FAP), which causes severe colon polyposis and colon cancer,
is caused by changes in the APC gene (Jasperson et al., 2017). An autosomal recessive
polyposis syndrome has also been identified, MUTYH-associated Polyposis (MAP),
which occurs when an individual inherits two PVs in the MUTYH gene (Nielsen et al.,
2019).
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There are other, rarer hereditary cancer syndromes as well. Peutz-Jegher’s
syndrome (PJS) is caused by PVs in the STK11 gene and causes increased risk for
hamartomatous polyps and pancreatic and other cancers (McGarrity et al., 2016). Von
Hippel-Lindau is caused by mutations in the VHL gene and increases the risk of renal
cancer (van Leeuwaarde et al., 2018). Familial atypical multiple mole melanoma
syndrome (FAMMM) causes melanocytic moles as well as an increased risk for
melanoma and has been linked to mutations on the CDKN2A gene (MedlinePlus
Genetics, 2020).
Li-Fraumeni Syndrome was first discovered in the 1960s and is linked to a
greater than 90% risk of some form of cancer by age 70. Individuals with this syndrome
are at higher risk of breast and colon cancer, but also childhood cancers, rare soft tissue
sarcomas, and many other types of cancers. Screening and risk reduction for individuals
with this syndrome can begin as early as childhood, and often need to be done at larger
cancer centers due to the complex nature of the screenings (Schneider et al., 2019).
This is just a brief summary of the most widely known cancer syndromes. PVs
now exist in over 30 genes associated with an increased cancer susceptibility, and in
another 30–50 that possibly cause an increased risk. With a higher volume of genetic
testing, more discoveries are being made (Milanese & Wang, 2019).
Types of Genetic Testing
There are several varieties of genetic testing that an individual might have if
hereditary cancer syndrome is suspected. Site-specific analysis would be used if a PV
has previously been detected in the family. In this case, analysis is focused on just
detecting the one variant, and does not analyze the whole gene, and could not detect
any other existing PVs (UW Medicine Laboratory for Precision Diagnostics, 2015a).
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Single gene testing is a slightly broader test. This might be used when tumor
analysis has indicated a possible PV in a specific gene, such as loss of MLH1 on
immunohistochemistry of a colon tumor. Other reasons to do single gene testing would
be cancers that are associated with a specific gene, such as diffuse gastric cancer and
CDH1 (Human Genetics Laboratory, 2019). These examples of single gene analysis are
also considered diagnostic testing, as the individual usually has a cancer associated with
the gene being analyzed (MedlinePlus Genetics, 2020).
Asymptomatic individuals may have genetic testing based on family history,
which would be considered screening (MedlinePlus Genetics, 2020). There are a variety
of guidelines depending on the type of cancers in the family, but in general, if a firstdegree relative would have qualified for testing and did not have it or the results are
unavailable, then their asymptomatic relative would be eligible. Additionally, having a
family history with multiple second- or third-degree relatives on the same side of the
family with certain cancers would be a reason for an individual to consider genetic
testing. It should be noted that the recommended strategy is to always begin with the
family member who has been diagnosed with cancer if at all possible (NCI, 2019).
Prenatal or preconception carrier screening is less common in hereditary cancer
syndromes than it is with other genetic syndromes (MedlinePlus Genetics, 2020; NCI,
2019). This is likely due to the fact that most of these cancers would not affect the
offspring until adulthood in most cases. Carrier screening might be done when there is a
family history of Li Fraumeni Syndrome, as this could affect very young children
(Schneider et al., 2019). Additionally, if one partner is a known carrier of a BRCA1/2 or
ATM mutation, the other partner may undergo screening; recessive conditions are
associated with these mutations (Fanconi anemia, ataxia-telangiectasia; Petrucelli et al.,
2016).
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Who Should Get Tested?
Criteria for who should get genetic testing vary by syndrome, but some common
guidelines exist. Testing guidelines for several hereditary syndromes are available from
groups such as the National Comprehensive Cancer Network (NCCN, 2020). Individuals
with a personal or family history of certain rare cancers should be assessed, as well as if
there is a history of cancers at unusually young ages (NCI, 2019). Members of certain
ethnic groups may also be at higher risk for hereditary cancer syndromes and therefore
should consider testing. One example is the Ashkenazi Jews, who have three founder
mutations in the BRCA1 and BRCA2 genes (Levy-Lahad et al., 1997). Anyone with a
family history of a known pathogenic variant in a close relative should be assessed to
determine whether testing is necessary, and anyone with a family history of multiple
cancers or certain patterns of cancer should be assessed to determine what testing is
needed (NCI, 2019).
Testing Process
Historically, individuals would be referred to a genetics specialist if a hereditary
syndrome is suspected, usually a geneticist or genetic counselor. The genetics specialist
would have a pretest visit with the patient, where they would gather three generations of
family history and the individual’s medical history. This would include cancer diagnoses,
surgeries, medications, and other medical details. The patient would also be educated
on genetics, possible outcomes, and the process. Insurance coverage and costs would
be reviewed, and the patient would have a sample collected if they choose to have
testing. The whole visit could last approximately 45–90 minutes, depending on the
facility’s processes.
Testing occurs mostly through a variety of commercial laboratories. Results can
take anywhere from 5 to 21 days (Ambry Genetics, 2020; Invitae, 2020) to process and
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can be disclosed to the patient in a few different ways. Some facilities disclose solely
through in-person visits, while others will reserve these visits only for individuals with a
PV and will disclose negative or VUS results over the phone unless a patient requests a
follow up-visit. Implications and recommendations for the results are discussed. A letter
is written summarizing the visit and the test results, as well as the recommendations for
screening and risk reduction. Referrals may be made to specialists, depending on what
further medical care is needed.
With the expansion of genetic testing, more individuals are seeking testing
without genetic counseling. Primary care, gynecology, gastroenterology, and oncology
are just a few areas where patients may receive genetic testing (Shields et al., 2008). In
fact, some genetic testing laboratories will market directly to providers in these areas.
Some may have training in genetics, but not all providers do. A misunderstanding of a
VUS on genetic testing due to a lack of knowledge can have serious consequences.
Additionally, the implication that their healthcare provider (HCP) doesn’t understand the
test result can cause increased stress and frustration for patients. Patients with a PV or
VUS detected on testing ordered by a non-genetic provider will sometimes be referred
for posttest genetic counseling.
Possible Results and Benefits of Genetic Testing
Genetic test results generally fall into three categories: positive, negative, or VUS
(Centers for Disease Control and Prevention [CDC], 2020). A positive test result means
that the genetic test found a pathogenic or likely pathogenic variant that is associated
with an inherited cancer-susceptibility syndrome. A positive result may give some
indication of the cause of an individual’s cancer, guide cancer treatment decisions,
indicate that an individual is at higher risk of cancer, as well as guide family testing. It
does not indicate that a person will definitely have cancer in their lifetime.
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A negative genetic test result means that in the genes that were analyzed, no
pathogenic variants were found. It does not mean that there is definitely no hereditary
cancer risk, as a pathogenic variant may exist in a gene that wasn’t tested. Management
of individuals with negative genetic test results depends on personal and family history.
A VUS test result means that genetic testing shows a variant that has not been
definitely associated with cancer risks. This result is uncertain, and the information does
not help to clarify individual risk and is not recommended for use in making healthcare
decisions. Some VUS may be reclassified as more population data is gathered, but this
process can take years. Most VUS are reclassified as benign. Recommendations for
screening and risk reduction are based on the individual’s personal and family history
(Schleit, 2019; University of Washington, 2015a).
Over the past decade, multigene panel testing for hereditary cancer risk has
expanded to include more than 60 genes. With this expansion, the chance of a VUS
increases. Exact VUS rates are difficult to estimate, as each lab reports this data
differently. It is reported that BRCA1/2 analysis, a genetic test that has been used for
more than 2 decades and only covers two genes, has a 1–3% chance of a VUS result.
For a 25-gene panel test, the chance increases to 30% or more (Idos et al., 2019;
Rosenthal et al., 2017).
Uncertainty of Having a VUS Test Result
A VUS result is uninformative. It therefore is not recommended that clinicians use
this information to decide on medical management strategies. Instead,
recommendations should be made based on personal and family history. For example, a
woman with a VUS and a family history of breast cancer in her mother at age 40 should
still consider mammography at age 35, according to current guidelines. Unfortunately, it
is not always clear to HCPs without training in genetics how to manage these situations.
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Occasionally a VUS will be overmanaged, leading to inappropriate surgeries; other times
it is undermanaged, which leads to missed opportunities for screening based on family
history. This confusion among healthcare professionals can lead to increased stress and
poorer outcomes for patients (J. G. Hamilton et al., 2019; Reuter et al., 2019).
Many studies have focused on the psychosocial impacts of a pathogenic result,
but few have looked at the effects of a VUS result. Through a better understanding of the
experiences of individuals living with this uncertainty, HCPs will be equipped to provide
more holistic care. The studies that have been conducted show that even if an individual
remembers the specific nomenclature of their test result, they do not necessarily
understand what it means for themselves and their family.
Communication
Good communication begins before the genetic testing. Expectations for the
process can be set by the referring provider. Genetic counseling visits are traditionally
face-to-face, but telehealth visits are expanding. During the counseling visit, it is
important that the provider ask clear questions about the patient’s personal and family
history of cancer and other diseases. The provider also needs to communicate about
potential outcomes of the process, such as what recommendations exist for managing a
pathogenic result. This is also when the patient should be informed of the possibility of a
VUS result. Counseling includes a discussion of emotional impacts of genetic testing, as
well as coping mechanisms and individual preferences. Patients are informed of legal
rights, and potential risks of testing. Informed consent is collected if the patient decides
to pursue testing.
Posttest results disclosure can occur via telephone, telehealth, or in person.
Facilities vary on their procedures, and often patients can choose what they prefer. The
results of the test, implications, and recommendations for follow-up are discussed. If a
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PV is identified, this may involve facilitating referrals to other specialties, and identifying
family members who should also consider testing. For a VUS or negative result, the
patient’s risks for cancer will be reassessed using various calculations, such as the
Tyrer-Cusik score for breast cancer (Ikonopedia IBIS, 2017). Ideally, patients with a VUS
will be advised to check in periodically for updates on reclassification, as it gives them
some control over recontact.
Communication is an important aspect of healthcare that has not been frequently
examined with regard to VUS results. Communication between family members
regarding genetic test results and medical history is important, as it can have
implications for future genetic testing, screening, and other risk-reduction measures.
Understanding these patterns and any barriers to communication will help provide
support to these families.
Similarly, communication between individuals and their HCPs regarding VUS
results is not well understood. A few studies noted confusion and frustration related to
this area. Frequently, genetic counseling is provided in a manner that educates the
patient regarding genetic testing, but not about handling uncertainty. Additionally, an
individual may only see a genetic counselor or other genetics specialist only once or
twice, and the remainder of their medical management is left to primary care or women’s
health providers. Because these individuals may not understand what a VUS is, they
may make incorrect or discordant recommendations to the patient. This can result in
either under- or overscreening, unnecessary testing and procedures, and negative
psychosocial impacts for the patient.
Although genetic counseling requires some specialized education, there is a role
for nurses at all levels of practice. Nurses working in oncology, gynecology, and primary
care are in a position to identify patients who should be referred to genetics. Nurses can
assist patients in understanding and following screening and risk-reduction guidelines.
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None of these activities require specialized education, and most of these skills can be
learned in the same way most nursing skills are learned—on the job.
Aims
In order to expand on the current knowledge of experiences of individuals with a
VUS result on genetic testing for hereditary cancer susceptibility, this study aimed to
answer the following research questions:
1.

What does having a VUS result for hereditary cancer susceptibility mean

to individuals for themselves and for their first-degree relatives?
2.

What is the experience of individuals with a VUS result for hereditary

cancer susceptibility in communication with healthcare professionals?
3.

What is the experience of individuals with a VUS result for hereditary

cancer susceptibility in communication with family members?
To accomplish the aims of this study, a constructivist grounded theory approach
was used. A constructivist approach acknowledges that the individual creates their
reality, and the researcher’s experience plays a role in interpreting data and developing
an explanatory theory. Purposive sampling was used to recruit at least 25 participants,
with efforts focused on capturing a more diverse population than had previously been
seen in other studies. Data were collected using semistructured interviews either by
phone or video/voice conference. Interviews were expected to last approximately 45–60
minutes. To identify initial codes, the research team began analyzing transcripts after
three interviews were completed. Subsequently, theoretical sampling and constant
comparison were used.
Importance
This study contributes valuable insights on the experiences of these individuals in
making sense of their test results as well as communicating with healthcare providers
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and family members. Clinically, this information identifies ways to improve genetic
testing experiences of for individuals with a VUS result.
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CHAPTER 2
SCOPING REVIEW
Objectives
The purpose of this scoping review was to identify the literature on experiences
of individuals receiving a variant of uncertain significance (VUS) on genetic testing for
hereditary cancer susceptibility. The research question was “What is the current
evidence on the experiences of individuals with a VUS genetic test result for hereditary
cancer susceptibility.” For this review, “experience” was defined broadly to include any
biological, psychological, or social effect of generic test result on individuals, whether
positive or negative.
Inclusion and Exclusion Criteria
Studies were deemed eligible if they (a) were original research published in the
English language, (b) exclusively or partially included individual with a VUS result in their
sample, (c) focused on an adult sample of any gender, and (d) included individuals
tested for any type of hereditary cancer syndromes with or without a personal history of
cancer. Studies that examined non-VUS genetic test results or non-cancer genes were
also included if either of these two areas were explored in addition to individuals with
VUS results in the gene associated with cancer risks. The articles with any type of
genetic testing—single gene, small panels, or multigene panels—were also included.
Exclusion criteria were review articles, dissertations, or topics not consistent with the
review's aims.
Search Strategy
We conducted this scoping review according to the recommendations outlined by
the Joanna Briggs Institute (Peters et al., 2020). The search was conducted in June
2020 using the PubMed, CINAHL, Web of Science, and PsychInfo databases. We used
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search terms to capture all possible articles to map current evidence on experiences of
individuals with a VUS result for hereditary cancer. The exact search used for PUBMED
was (hereditary cancer risk OR hereditary cancer syndrome) AND (experience OR need
OR belief OR attitude OR reaction OR perception OR perspective OR consequence OR
view)) AND (VUS OR variants of uncertain significance). Similar combinations were
used for CINAHL, Web of Science, and PsychInfo. Preliminary search to decide
databases and the search term was conducted with the consultation of library liaison for
UMass Amherst College of Nursing.
Study Selection
We used the RefWorks reference manager to manage citations from multiple
databases. All titles and abstracts that we identified in the search process were imported
into RefWorks. An initial identification and removal of duplicates were conducted using
the automated feature in RefWorks. The remaining articles were then imported into
Rayyan QCRI (https://rayyan.qcri.org). A manual check for duplicates was then
performed. An initial title scan was conducted, followed by a scan of the abstracts. The
full text of any articles identified as relevant after the abstract scan was obtained. Full
texts of included articles were retrieved and reviewed by the researchers using the
inclusion and exclusion criteria resulting in a final sample of articles. The reference lists
of the full text of all articles identified seven articles, which were also assessed against
the inclusion criteria, resulting in a final sample of 19 articles. The results of the search
process are depicted in the Preferred Reporting Items for Systematic Reviews and Metaanalyses (PRISMA) flow diagram (Figure 2.1).
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Figure 2.1: PRISMA flow diagram.

Data Extraction
Data was extracted from the eligible articles using a table developed by the
author based on the chart's key information suggested by Joanna Briggs Institute
(Peters et al., 2020). In addition to the authors, the year of publication, and the country of
origin of the articles, the extracted data included study aims, genetic test results for the
sample, sample size and characteristics, assessment and measures, methods, results,
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and interpretation or recommendations. A narrative summary accompanies the tabled
results with a description of how the results relate to this review's objectives (Appendix
A).
Description of the Studies
Of the 19 studies included in our final review, 13 were conducted in the United
States, and one was conducted both in the U.S. and Canada. The remainder were
conducted in Canada (n = 1), Europe (4), and Singapore (1). A quantitative design was
used by 11 of the studies, qualitative design was used in six studies, and two studies
used a mixed-methods design. There were six studies using a prospective approach,
while 13 were retrospective. The sample consisted of only women in 11 of the studies,
men were included in only two of the studies, and six included any gender. Probands
were the focus of 16 studies, probands and families in two studies, and probands and
clinicians in one study.
A theoretical framework was used in only a small proportion of the reviewed
studies (n = 5). Mishel’s Theory of Uncertainty in Illness was utilized by two studies
(Reuter et al., 2019; Solomon et al., 2017). A grounded theory model was utilized by Li
et al. (2018). Vos (2008) used the distorted perception hypothesis. Makhnoon, Shirts, et
al. (2019) used Han’s Taxonomy of Uncertainty as a framework.
The sample of the studies had undergone multigene panel testing in nine studies
(Conley et al., 2019; Esteban et al., 2018; Garcia et al., 2014; Giri et al., 2018; Li et al.,
2018; Makhnoon, Garrett, et al., 2019; Makhnoon, Shirts, et al., 2019; Reuter et al.,
2019; Tsai et al., 2020). J. G. Hamilton et al. (2019) examined a population that had
testing for CDH1 variants, which causes hereditary diffuse gastric cancer, and Solomon
et al. (2017) examined individuals who had testing for gene mutations associated with
Lynch syndrome. Another eight studies examined a population who had genetic testing
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for BRCA1 or BRCA2 gene mutations only (Brédart et al., 2019; Chern et al., 2019;
Culver et al., 2013; Cypowyj et al., 2008; Elsayegh et al., 2018; Miron et al., 2000;
Richter et al., 2013; Vos et al., 2008).
Of studies included in this review, seven only included individuals with VUS
results (Cypowyj et al., 2008; Makhnoon, Garrett, et al., 2019; Makhnoon, Shirts, et al.,
2019; Reuter et al., 2019; Solomon et al., 2017; Tsai et al., 2020; Vos et al., 2008). Two
studies compared individuals with a VUS result with those who had a negative test result
(Chern et al., 2019; Culver et al., 2013). A sample with a VUS result was compared with
those who had a positive result in four studies (Garcia et al., 2014; Giri et al., 2018; N.
M. Hamilton et al., 2017; Miron et al., 2000). In six studies, samples with different genetic
test results including a VUS result, positive, or negative result were compared (Brédart
et al., 2019; Conley et al., 2020; Elsayegh et al., 2018; Esteban et al., 2018; Li et al.,
2018; Richter et al., 2013).

Table 2.1: Descriptive characteristic of studies included in the scoping review.
N
Country

Study design

Sample

%

USA

12

63.16

USA and Canada

1

5.26

Canada

1

5.26

France, Germany, and Spain

1

5.26

France

1

5.26

Spain

1

5.26

The Netherlands

1

5.26

Singapore

1

5.26

Quantitative

11

57.89

Qualitative

6

31.58

Mixed

2

10.53

Women only

12

.16

Men only

1

5.26

15

6

31.58

10

52.63

Communication with healthcare provider

9

47.37

Family communication on the test result

5

26.32

Emotional/Psychological effects of test
result

10

52.63

Risk perception for cancer

6

31.58

Screening and risk reducing surgery
decision-making

7

36.84

BRCA 1/2 genes

9

47.37

Lynch or single gene

2

10.53

Multigene panel

8

42.11

VUS only

7

36.84

PV or VUS

4

21.05

Negative or VUS

2

10.53

PV or VUS or Negative

6

31.58

2000-2004

1

5.26

2005-2009

3

15.79

2010-2014

3

15.79

2014-2020

12

63.16

Any gender
Outcome measurements Recall/ understanding of the test result

Type of genetic test

Results of sample

Publication date

Study Results
Understanding, Knowledge, or Recall
Measurements of knowledge, understanding, or recall of test results were
included in 11 of the studies included in this review (Conley et al., 2020; Cypowyj et al.,
2008; Esteban et al., 2018; Giri et al., 2018; J. G. Hamilton et al., 2019; Makhnoon,
Garrett, et al., 2019; Makhnoon, Shirts, et al., 2019; Reuter et al., 2019; Richter et al.,
2013; Solomon et al., 2017; Vos et al., 2008). A common theme was a lack of
understanding or recall of the VUS result. Giri et al. (2018) found that having a VUS
result was associated with this lack of understanding, versus a different result, and other
factors such as literacy did not explain this phenomenon. In Giri et al.’s study, 101
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participants stated that they understood their results, but 80 of these individuals
incorrectly responded that they carried a PV. This study also found that a VUS was
associated with misunderstanding. In J. G. Hamilton et al. (2019), 12/56 participants
stated their results incorrectly; Reuter et al. (2019) found 2 out of 14 participants did not
recall having a VUS at all; Cypowj et al. (2008) showed that the group with a VUS had
the highest rate of incorrect recall (36%). Richter et al. (2013) found that those with a
VUS had the highest rate of incorrect recall (36%); Vos et al. (2008) found 79%
interpreted a BUS as a PV. In Solomon et al. (2017), 7 individuals stated that they did
not have Lynch Syndrome.
There are some studies showing the misunderstanding about the
recommendation after having a VUS result. Makhnoon, Garrett, et al., (2019) found that
individuals misunderstood the recommendations of their HCPs, while Makhnoon, Shirts,
et al. (2019) described the misunderstandings as a “non-technical conceptual
ambiguity.” Esteban et al. (2018) noted that those with a high-penetrance PV reported
that they understood their recommendations more than those with a VUS or moderate
penetrance PV. Reuter noted that most did not understand that a VUS didn’t impact
medical management.
Communication
In this review, six of the included studies examined aspects of family
communication on genetic test result and the risk for cancer. N. M. Hamilton et al.
(2017), Cypowj et al. (2008), and Solomon et al. (2017) found that most participants had
communicated the test results to their family members. Cypowj et al. showed that 76%
had communicated the information within 2 years after the test, with most of these
individuals doing so because of a misunderstanding whether their family members would
need to know this result.
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Various motivations of the proband to share the test results were reported in the
studies. Participants in the Tsai et al. (2020) study were motivated by a desire to help
their families. Both Li et al. (2018) and Tsai et al. found that some participants were
cautious about sharing the result because a VUS was considered confusing and a desire
not to cause a false alarm. Conley et al. (2020) found that there were discrepancies in
disclosure based on family members.
Some studies also reported the factors influencing the decision to communicate
the test result with family members. Li et al. (2018) noted a willingness to share based
on closeness and a feeling of duty. Cypowj et al. (2008) noted that a belief that the
family members also needed tested or increased surveillance resulted in sharing the
information with family members. VUS results were less likely to be shared if the
proband did not think they would be useful for the family or did not think the family
members would understand them (Li et al., 2018). In one study looking at variant
reclassification, discussing the VUS led to more discussions about family medical history
(Makhnoon, Garrett, et al., 2019).
Nine studies examined communications with HCPs. The two studies by
Mahknoon et al. (2019) found that pretest preparation for a possible VUS was more
effective in improving understanding of the test result. They also found that participants
were frustrated with providers and felt their worries were dismissed. J. G. Hamilton et al.
(2019) found that 45.6% of participants recalled being informed about the possibility of a
VUS result during pretest counselling and that those with a VUS result were less
satisfied with provider’ knowledge. Culver et al. (2013) found that different counseling
styles influenced risk perception and that assisting in making decisions about medical
care was most helpful. Richter found that genetic counselors would make
recommendations to patients with a VUS result based on personal or family history.
They also found that most physicians would incorrectly refer the family members of a
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patient with a VUS for genetic testing. Esteban et al. (2018) noted that most participants
wished to be disclosed VUS and variants in moderate penetrance genes. Conley et al.
(Conley et al., 2020) found that the only factor affecting the test result disclosure in the
family that significantly varied by test result was whether a provider encouraged them to
tell their families. Giri et al. (2018) noted that results disclosure via telephone or
telehealth was associated with misunderstanding of test results.
Emotional and Psychological Outcomes
A total of nine studies examined emotional or psychological outcomes, including
worry, anxiety, depression, or other feelings after having test results. Brédart et al.
(2019) found that women with a negative result or a VUS result showed a decrease in
scores for concerns about hereditary predisposition. Getting psychological help after
testing was associated with problems in the “emotions” domains. Culver et al. (2013)
found that the VUS group in their study reported a significant change in concerning
thoughts, with 92% reporting a decrease after having the test result. Richter et al. (2013)
found that individuals with a VUS result had intermediate scores on the Trask Worry
Scale, which was significantly different than those with a PV. Esteban et al. (2018)
measured worry and found that scores did not differ significantly over time or by test
result. Also, patients with a positive test result had more distress than those with a VUS
or negative result.
Emotional reactions to having a VUS result were varied in the studies. Reuter et
al. (2019) found that emotional responses varied, but most participants did not think
about the VUS result very often. Solomon also found varied reactions, from relief to
shock experienced by proband after having their VUS result. They also found that 17
appraised the result as a threat, 17 as an opportunity, and 6 as both; mobilizing or
planning was the most common coping mechanism. Tsai et al. (2020) found that
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participants’ stress and anxiety largely originated from misunderstanding of the VUS
result, but most reported a neutral to positive impact on their emotions. Some
participants in the Makhnoon, Shirts, et al. (2019) study reported a negative affect after
disclosure by their provider or felt frustration with providers who dismissed their worries;
others felt relief or indifference.
Risk Perception for Developing Cancer
Only five studies examined risk perception specifically in those with a VUS
(Culver et al., 2013; J. G. Hamilton et al., 2019; Makhnoon, Garrett, et al., 2019; Miron et
al., 2000; Vos et al., 2008). In Culver et al. (2013), 15% of those with a VUS considered
themself high risk, while only 10% of those with a negative result did. Participants with
both PV and VUS results, in the J. G. Hamilton et al. (2019) study, reported their risk at
midpoints on the Likert scales. Miron et al. (2000) reported significant differences
between self-estimated risks and calculated risks. Makhnoon, Shirts, et al. (2019) found
uncertainty and unclear interpretations regarding risks, while Vos (2008) showed that
both the VUS and negative groups reported decreases in perceived risk.
Screening and Risk Reduction
No study examined screening uptake based on what is appropriate given a VUS
result and family history; however, five studies investigated various aspects of cancer
screening uptake (Garcia et al., 2014; J. G. Hamilton et al., 2019; Makhnoon, Garrett, et
al., 2019; Solomon et al., 2017; Tsai et al., 2020). In Makhnoon, Shirts, et al. (2019),
some participants wanted more frequent screening; Tsai et al. (2020) found that some
already thought their medical care was sufficient for their VUS result. Solomon et al.
(2017) noted a perceived benefit from a management plan. In J. G. Hamilton et al.
(2019), 69.2% of participants with a VUS had a breast MRI, and 92% had mammograms
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at least yearly, and 6% had upper endoscopy. Garcia et al. (2014) noted a low rate of
ovarian cancer surveillance for both PV and VUS groups, which dropped every year.
Decisions on risk-reduction surgery were examined in six studies (Chern et al.,
2019; Culver et al., 2013; Elsayegh et al., 2018; Miron et al., 2000; Richter et al., 2013;
Vos et al., 2008). Chern et al. (2019) and Culver et al. (2013) found no significant
differences in surgical decisions for those with a VUS versus a negative result. In Culver
(2013), all individuals who had a bilateral salpingo-oophorectomy (BSO) met guidelines
for surgery based on personal or family history. Miron et al. (2000) found that three out
of four of those with a VUS who were interested in risk reducing BSO before the test
changed their minds after having their test results. Richter et al. (2013) and Elsayeh et
al. (2018) both found that those with a VUS had lower contralateral prophylactic
mastectomy (CPM) rates than those with a PV. Elsayeh examined CPM uptake and
found a lower election in individuals with a VUS versus a PV result, but the difference
was not significant. Age and not hormone receptor status of the tumor were associated
with the CPM election in the VUS group. Vos et al. (2008) found that seven individuals
had a mastectomy due to the VUS and three due to cancer, and found no difference in
surgeries between PV and VUS groups.
Discussion
Recall or knowledge of the VUS result was generally poor among individuals with
a VUS result. Many individuals recalled not having a VUS at all. Some reported having a
negative result or would state that they had a PV result. In one study some individuals
recalled that they did have a VUS result, but they still interpreted it as a pathogenic
result. Some individuals referred their family members for testing because they were not
aware that this was not routinely needed for a VUS (Cypowyj et al., 2008). There is an
interesting differentiation between actual test result and personal interpretation of the
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test result, implying that more than simple recall goes into the meaning of the result for
the individual (Vos et al., 2008).
There were also some results indicating that HCPs, especially non-genetics
providers, made incorrect recommendations regarding testing for family members or
screening of probands with a VUS (Richter et al., 2013). This leads to more confusion for
the individuals with a VUS genetic result, and it is another opportunity for improved
communication not only between healthcare providers and patients but also between
genetics specialists and non-genetic healthcare providers. It may also show the need for
education among non-genetics healthcare providers.
Individuals with a PV result generally understood their results and screening
options much better than those with a VUS. Few studies examined risks or screening
uptake directly in individuals with a VUS. This would require an understanding of each
participant's family history to know if the individual met criteria suggested by guidelines
for increased screening or risk-reduction surgery. As noted before, the personal
interpretation of a VUS result as pathogenic or benign appears to have consequences
on risk perception (Vos et al., 2008). This shows that some individuals thought they were
at higher risk when they were not, leading to frustration with a perceived lack of care
(Makhnoon, Shirts, et al., 2019). Some individuals appeared to understand a VUS result
as a negative result and did not think that they could still be at elevated risk for cancer.
This has potentially dire consequences if the patient is in fact at high risk and does not
get recommended screenings or ignores their symptoms. Regarding surgical decisionmaking, in most of the studies individuals who opted for surgeries and had a VUS met
guidelines due to some other factors such as personal cancer history or family history.
Although there are no definitive guidelines for management of individuals with a VUS,
they may be eligible for increased screening or risk-reduction options based on risk
assessment including personal or family history of cancer. High-risk individuals could be
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recommended to have early mammography or colonoscopy, breast MRI, as well as
pharmacological and surgical options (NCCN, 2020).
The studies that examined communication with family members found that
participants were less willing to share VUS test results than PV test results. The reasons
for this were that the VUS results were confusing to explain, would not help their family,
and might cause more harm than good (Makhnoon, Shirts, et al., 2019). If the proband
thought that the VUS could potentially help their family members, they tend to
communicate the results. In one study that examined the participation of family members
in a reclassification study there was some paternalism noted, in that older individuals
wanted to tell their family members what to do, however most of the family members
surveyed were happy to participate in order to help their family.
Emotional reactions to receiving a VUS result ranged from relief to distress.
Overall, there was less distress among individuals with a VUS result then those with a
PV result. Confusion and frustration are also frequently noted by studies examining
emotional response. Overall life changes related to the VUS result were not significant,
and studies investigating intrusive thoughts did not find that individuals with a VUS
frequently thought about it. Moreover, participants often noted they would rather have a
definitive result, even if it were a PV result. As a coping strategy, it was reported that
interpreting a VUS result as pathogenic and acting as if it was pathogenic may allow for
individuals to make more conservative plan (Solomon et al., 2017).
Probands appeared to misunderstand whether they did get the medical care that
they perceived as needed (Makhnoon, Garrett, et al., 2019). For instance, patients with a
VUS who perceived themselves as high-risk expected more screening, even if it was not
supported by current evidence related to test result and their personal or family history.
These individuals indicated they felt “brushed off” by their healthcare provider
(Makhnoon, Garrett, et al.). This is an area where better communication between HCP
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and proband is needed regarding actual risks and recommendations based on the
compressive risk assessment.
In individuals with a VUS result, there tended to be less satisfaction with their
HCPs when compared with individuals who had a PV or negative result (J. G. Hamilton
et al., 2019). In a few studies, participants expressed frustration with their healthcare
provider due to a perceived lack of knowledge of providers (Makhnoon, Garrett, et al.,
2019). It may show that the patients did not understand that a VUS was uncertain
because of a lack of scientific evidence and not due to a lack of knowledge by the
healthcare provider. There was also a trend towards patients who were being prepared
pre-test for the possibility of a VUS to be more knowledgeable and more satisfied with
their care. This may indicate a need for greater focus on a possible VUS result to ensure
the proband understand the limited evidence on the implications of a VUS result for
proband and their families during pre-test counseling.
There are some methodological issues on the articles included in this review:
The design of the study, lack of diversity in sample, and lack of comparison among
individuals with different test results. Most of the studies utilized a thematic analysis or
qualitative description; none used standard grounded theory. Li et al. (2018) used
grounded theory methods but did not state that they followed all the necessary parts of
the methodology. The different designs make it hard to compare the findings from these
studies. Of the six qualitative studies, five focused exclusively on individuals with a VUS
and one compared a VUS with a PV or negative result. This indicates a methodological
area that has not yet been explored in order to better understand the needs of
individuals with a VUS. Although thematic analysis and other interview-based studies do
provide insight into the experiences of the individual, they may not be used to make
explicit conclusions from these studies.
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Only one study focused exclusively on men (Giri et al., 2018), with six studies
including both men and women (Esteban et al., 2018; J. G. Hamilton et al., 2019;
Makhnoon, Garrett, et al., 2019; Reuter et al., 2019; Solomon et al., 2017; Tsai et al.,
2020). In those studies, less than half of the sample was male. This could be a function
of several of the studies focusing on women with breast cancer, or the time frame of the
study was when testing criteria was more stringent. However, this highlights that men
are frequently left out of research regarding genetic testing for hereditary cancer
syndromes, as the focus is frequently on breast and ovarian cancer risk. It is important
that men be included in this research, because even if they do not have the highest
associated risks, they may still have risks and will also play a role in the family
communication surrounding testing. Additionally, there were no studies that noted
whether their sample included nonbinary and transgender individuals. This is again
problematic, as excluding or miscategorizing these individuals will impact our
understanding of risks, perception, and experiences with genetic testing. It ultimately
prevents us from using the results of expanded genetic testing to reduce cancer risks.
Black, indigenous, Hispanic, and other people of color have historically been
underrepresented in research on genetic testing, and the same is true in this review.
Whites make up a vast majority of the sample in studies set in the United States, where
the general population is much more racially diverse. One study found that the group
with a VUS is more racially diverse, which is likely due to lower rates of testing in nonwhite, non-European groups. This lack of diversity limits the generalizability of study
findings and continues to perpetuate inequities in genetic testing.
Limitations
The scoping review method used here has some limitations. Due to their nature,
scoping reviews provide a broad overview of the existing literature, but do not deeply
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analyze the quality of the evidence. It is also possible that due to the time-limited nature
of the search and choice of search terms, some studies may have been missed in this
review.
Recommendations
This review established that individuals with a VUS result have the lowest level of
recall and understanding of their test results. Clinicians who are providing VUS results
should focus on supporting the patient’s knowledge. Research should focus on methods
of education that most support the patient’s understanding of a VUS result.
Communication between family members regarding genetic testing, and
specifically regarding VUS results, needs further investigation. Methods to support and
encourage open communication regarding results and medical history should be
identified. More studies examining causes of confusion with recommendations is also
needed. Clinicians should include a discussion of family communication within their
counseling visits, including identification of which relatives to speak to and strategies to
do so.
Although the studies in this review showed that individuals with a VUS result had
better emotional outcomes compared with those with a PV, continued research into the
factors impacting emotional or psychological outcomes in this group would improve the
counseling process.
Risk perception was at least in part dependent on understanding and knowledge;
therefore similar studies are needed that examine the factors influencing risk perception.
Based on current evidence, clinicians should pay close attention to signs that the patient
is not understanding the information.
A skewed risk perception can impact screening and risk reduction. Although the
studies examining surgical decisions did include some analysis of whether surgery was
appropriate according to guidelines, a detailed examination of family history in
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individuals with a VUS was not included. More studies are needed that look at whether
individuals with a VUS result are getting appropriate medical management based on
histories. Furthermore, it is clear that education and support for the clinicians who are
managing these individuals is needed.
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CHAPTER 3
METHODS
Aims
The aim of this qualitative study employing grounded theory methodology was to
explore the experiences of individuals who had a VUS result on genetic testing for
hereditary cancer syndromes. This study focused specifically on their experiences and
needs in interpretation of the test result for their selves and their family members and the
process of communication with healthcare providers and their first-degree relatives about
genetic risk and risk management.
Research Questions
1. What does having a VUS result for hereditary cancer susceptibility mean to
individuals for themselves and for their first-degree relatives?
2. What is the experience of individuals with a VUS result for hereditary cancer
susceptibility in communication with healthcare professionals?
3. What is the experience of individuals with a VUS result for hereditary cancer
susceptibility in communication with family members?
Design
This qualitative study used constructivist grounded theory, as described by
Charmaz (2014). This version of grounded theory acknowledges that social reality is
constructed, and the researcher cannot be a passive, neutral observer. Both participants
and researchers bring something to the interactions. Research is a construction, and we
might not be aware of all the conditions surrounding it (Charmaz, p. 13). For this study,
constructivist grounded theory was chosen as it places emphasis on symbolic
interactionism, where the individual makes meaning through words, symbols, and
objects.
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Sampling Strategy
This study used purposive sampling to initially recruit at least 25 individuals who
met our eligibility requirements. Purposive sampling involves selecting participants based
on specific characteristics. This method of sampling allows for recruitment from various
characteristics, such as personal cancer history, cancer types, age, gender, or
recruitment methods form support groups and referrals from local HCPs. It also enhances
reliability of the study by recruiting a larger sample. As in purposive qualitative sampling,
theoretical sampling involves selecting participants based on specific characteristics.
In grounded theory studies, theoretical sampling occurs as the data collection
progresses. If specific themes become more of a focus during the interview process, we
will choose subsequent interviewees based on the theoretical needs (i.e., cancer history,
genes tested, age, gender or type of provider) or alter the interview guide to focus more
on these areas. Using theoretical sampling allows for “the creation of full and robust
categories” (Charmaz, 2014, p. 200), as well as making better distinctions between
experiences. Theoretical sampling is at the center of grounded theory’s abductive
reasoning that allows inferences made regarding experiences supported by empirical
evidence (Charmaz, p. 201). It also allows for identifying gaps in understanding to be
identified, which results in a thicker description of experiences. Interviews will continue
until theoretical saturation is reached (Charmaz, p. 214), meaning no new insights are
generated after three interviews.
Recruitment
Recruitment occurred through the local community, support groups, and social
media. Sample recruitment messaging is included in Appendices B and C. An initial
recruitment goal of 25 was set during the proposal phase, with a deadline of June 1,
2021. At that time the recruitment goal had not been reached, and existing data was

29

reviewed to determine if it was sufficient to proceed to the next phase of coding and
analysis. More data was needed, so recruitment was extended through July 2021, at
which time 20 participants had been recruited, and the data collected was sufficient to
complete the final rounds of coding and analysis.
Inclusion Criteria
Over age 18
Able to speak English and connect via telephone or video chat
Had a VUS on a genetic test for hereditary cancer risks
Has access to or recall of the result nomenclature
Exclusion Criteria
VUS in non-cancer related gene
Diagnosed with any mental health problems
Ethical Considerations
This study was approved by the Institutional Review Board at the University of
Massachusetts Amherst (Appendix D). All participants were provided with informed
consent prior to participation in the study (Appendix E). Funding was not available to
provide monetary incentives to the participants. Participants were allowed to end their
interview at any time and to request that the recording be stopped and deleted.
Data Collection
Pre-interview Assessment
In order to ensure a consistent sample that met our inclusion criteria, participants
first completed a screening survey (Appendix F), followed by a pre-interview demographic
survey if eligible (Appendix G). Informed consent (Appendix E) was completed at the
beginning of the demographic survey. These surveys included the following:
Test results (personal information removed)
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Demographics
Personal and family history of cancer (3-generation)
Contact preferences
Preferred interview time
The entire instrument is available in Appendix E.
Outcomes Assessment
Data was collected through semistructured interviews conducted via secure video
chat or by phone. The primary investigator (PI) was the interviewer. Interviews were
recorded with permission from the participant and transcribed via an automated service.
The PI verified the transcriptions. Notes were taken during the interviews. The interview
guide appears as Appendix H.
Data Management Plan
All recordings, transcripts, and memos were stored locally on the researcher’s
password-protected and disk-encrypted computer. Study-related documents that needed
to be shared with committee members were uploaded to Box, which is a secure cloud
storage platform. Transcription was completed with the NViVo service or Otter.aI. NViVo
12 for Mac was used for analysis.
Data Analysis
Coding Strategy
Coding began with the first interview. As is consistent with grounded theory, no
coding schemes were developed before analysis began. Comparative methods were
used throughout the analysis, not only comparing codes, categories, and themes, but
also the researcher’s experience, as is suggested by Charmaz (2014, pp. 132–133). In
vivo codes were used for initial coding, as they reflect the meaning of the participants'
experiences in their own words (p. 135). Focused coding was used for the second round
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of analysis to reveal gaps or trends in data, as well as preconceptions (p. 143). Codes
were sorted along with memos into categories that supported further development of the
theory. Diagramming was also used to identify how different categories relate to each
other and what the underlying processes were. The developing theory was compared
back to the data throughout the process.
Trustworthiness
Memo writing by the researcher occurred throughout each step of the study
through note-taking and journaling on problems, ideas, and notes on the data (Charmaz,
2014, p. 169). This provided a place to document the research process in detail and a
way to analyze and speculate about the ongoing data collections and analysis (p. 171).
Memos provided a useful reflection about how codes and categories were developed and
enhanced trustworthiness.
To further enhance trustworthiness, coding was completed by the PI and the
dissertation advisor. Discrepancies were discussed until agreement was reached or
brought to the entire committee for discussion. Peer review and expert consultation were
also used.
Additional strategies to optimize the study's trustworthiness were reflexivity, which
was enhanced by the use of memos. A constructivist approach does not require the
researcher to set aside their experiences; it views the resulting theory as a creation of the
interactions between researcher and participant. Therefore, the researcher does not try to
take a naive approach, as other versions of grounded theory require.
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CHAPTER 4
FINDINGS
Research Questions
The purpose of this grounded theory study was to improve our understanding of
the experiences of individuals with a VUS identified on genetic testing for hereditary
cancer susceptibility. The specific research questions were the following:
1. What does having a VUS result for hereditary cancer susceptibility mean to
individuals for themselves and their first-degree relatives?
2. What is the experience of individuals with a VUS result for hereditary cancer
susceptibility in communication with healthcare professionals?
3. What is the experience of individuals with a VUS result for hereditary cancer
susceptibility in communication with family members?
Target Population
The target population of this study were adults who have had at least one VUS on
genetic testing for hereditary cancer susceptibility. Inclusion criteria were age 18 or
above, able to speak in English, able to connect via telephone or chat, had a VUS on a
genetic test for hereditary cancer susceptibility, and access to or recall of the result
nomenclature. Exclusion criteria were having a VUS in only a non-cancer related gene,
and diagnosis with any severe mental health problems (self-report).
Recruitment
Several recruitment methods were used to enlist eligible participants for the study
(see Table 4.1). Initially, a survey link was shared via social media, including Twitter and
Facebook. This yielded only three individuals who completed the screening survey. The
repeated attempts at recruitment via social media failed to yield additional participants.
Therefore, we partnered with PROMPT (https://promptstudy.info/) and FORCE
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(https://www.facingourrisk.org/) to recruit from a more targeted population. Of note, the
audience who likely saw the Twitter advertisements were more likely to be involved in
academia, as this makes up most of the network of the author’s followers and any
colleagues who shared the study information. On Facebook, the population was likely
more varied in education and profession, as these were personal contacts.
Table 4.1: Recruitment by method.
Source
Social media (Facebook,
Twitter)
PROMPT
FORCE
Totals

Screened
3

Eligible
1

Consented
1

Completed
1

29
5
37

29
4
34

20
4
25

15
4
20

The Prospective Registry Of MultiPlex Testing (PROMPT) is a registry of
individuals with variants on multigene testing. These individuals receive an initial
invitation to participate with their genetic test results from many commercial laboratories
in the U.S. The PROMPT team uses this information to understand the risks associated
with variants and partners with other researchers to share their data. They maintain an
email list, which is how participants received invitations to this study. The invitations were
sent out in batches of 50 or 100. A total of 29 individuals recruited from PROMPT filled
out the screening questionnaire, and 15 completed the study.
Facing Our Risk Empowered (FORCE) is a group that seeks to improve the lives
of individuals with cancer and their families. They provide both peer support and expert
information. The FORCE website has a research page that features various studies their
members may be interested in. This study was posted to the research page from March
to July 2021. A total of five individuals who completed the screening found the study
through FORCE, of whom four completed the study.
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In total, 37 people completed the screening questionnaire, and 34 were identified
as eligible to participate. Of these, 25 consented to the study and provided demographic
information, and 20 completed the interview portion. Similar qualitative studies identified
in Chapter 2 had response rates of 11%–60%, and quantitative studies reported
response rates of 17%–90%.
Data Collection
Interested individuals filled out a screening questionnaire on Qualtrics that asked
about genetic test results and contact information. After this information was reviewed,
eligible individuals were asked to complete a second survey that asked questions about
demographics, history, and scheduling. If participants missed an interview or did not
schedule, they were sent up to two reminders, and if at that point they did not complete
the study, they were not contacted again.
Primary data collection was done through semistructured interviews conducted by
the investigator. The interview guide (shown in Appendix H) was developed based on
prior experience, the review of literature, and the research questions. The guide
consisted of four broad questions, with 3–6 suggested prompts to use if the participant
was having difficulty answering. A fifth question, “Is there anything else you would like to
tell me?” was included in order to catch any other details of the individual experience
(Charmaz, 2014). All interviews were conducted via Zoom or Skype due to the need for
social distancing during the COVID-19 pandemic. Interviews ranged from 15–36 minutes.
The interviews were transcribed using Otter.AI, and the primary researcher verified the
transcripts. Verified transcripts were then loaded into NViVo for coding.
Sample Description
A total of 20 individuals completed an interview. See Table 4.2 for participant
demographics. The average age was 51.25 years (28–81 years). Fourteen participants
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identified as female, and although we asked if assigned sex at birth differed from their
gender, none responded Yes. Less than half of the sample was white (5 Black/African
American, 3 Asian, 1 Native American or Alaskan, 2 multiracial, 7 white). None identified
as Hispanic or Latinx. The education level was Graduate or Advanced degree in 11
participants; 11 were working full-time. Regarding insurance coverage, 18 participants
had private health insurance, and all stated their insurance covered genetic testing.
Table 4.2: Descriptive characteristics of the participants (N = 20).
Category

#

%

Age

-

51.25 (28–81)

-

Sex

Female

14

70

Male

6

30

White

9

45

Black/African American

5

25

Asian

3

15

Native American/Alaskan

1

5

Two or more

2

10

Hispanic

No

20

100

Education

High school

1

5

Some college

1

5

4-year degree

7

35

Grad school/Advanced degree

11

55

Full-time

11

55

Part-time

2

10

Unemployed/not looking

3

15

Retired

4

20

Private

18

90

Medicare

1

5

Military/VA

1

5

0

7

30

1

12

60

2

1

5

0

4

20

1

9

45

2+

7

35

0

4

20

1

9

45

2+

7

35

Race

Work Status

Insurance status

Personal History of Cancer

Cancer in first-degree relatives

Cancer in a second-degree or
higher relative
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Analysis
Coding
Each interview transcript was read in its entirety by the primary researcher and
then open-coded in vivo. A second pass was then done to merge codes with similar
meanings (Charmaz, 2014; Saldaña, 2021). The dissertation advisor read the interviews
and reviewed codes and provided input. Any disagreements regarding codes were few
and were resolved through discussion. The final codes and descriptions are delineated in
detail below, categorized logically by time period, and subcategorized by theme (Graff &
Birkenstein, 2006; Pacheco-Vega, 2017, 2021).
Analytic Memoing
Memos include notes taken during interviews and coding and drafts and sketches
of theoretical models that were done during the analysis process (Charmaz, 2014;
Saldaña, 2021). Comments made on the manuscript as the writing of the findings
progressed, and emails between the researchers, also served as memos. These memos,
although not coded, provide insights that contributed to the overall analysis and theory
development.
Researcher Positionality
An important factor in grounded theory research is the positionality of the
researcher (Charmaz, 2014). It is not possible to completely remove the influence of the
researcher on the research; therefore, it is critical to acknowledge it. The researcher is a
white, cisgender woman with an advanced degree in nursing and experience as a
clinician working with individuals during the genetic testing process. She has never had
genetic testing for hereditary cancer, nor have any of her family members. Any of these
factors could influence the analysis and interpretation of this research. This positionality
was kept in mind during the coding and thematic process. As the themes were
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developed, the codes and categories were scrutinized as to whether they were correctly
describing the meaning of the participant’s words, and not the researcher’s own opinions.
Categories and Codes
The codes have captured experiences during the three periods including the
pretesting process, testing process, and posttesting process (immediate and long-term
period).
Table 4.3: Summary of the codes and categories.
Category

Code

Example(s)

Pretest experience (Time before genetic counseling or genetic testing visit)
Motivations/
Reasons for
testing
Family history of
cancer

So now I've got a father and two uncles with it and a couple of
cousins, male cousins with prostate cancer.” “My mother's father had
bone cancer, not really sure where it came from, but he was a
smoker. Okay. And that's all.” “I think, for me, it had more of an
impact on what it was because my sister was diagnosed six months
after me.

Personal history of
cancer

I have an aggressive growth and so it slaughtered me
Yeah, we did find a growth in your abdomen area. We don't can't say
for sure what it is.
So about a month after the genetic testing results came back, I was
supposed to have my prophylactic mastectomy. But the last
sonogram that they did, they found breast cancer.

HCP recommended No, I had not considered it on my own. I really wasn't even aware
that it never crossed my mind to do this before. If if there would have
been like breast cancer, that type of genetic type of cancers, then
maybe but that had none of that in my family?
Concern for family

Both my mom and I had breast cancer, and I don't want my daughter
to get breast cancer. That's the only thing that I think about, that's all
that matters.
I thought of my child, it wasn't really about me at that moment, like I
need to do what I need to do to be healthy to be here for her.”

Communication
with family
members
Family data
collection

Family member
testing status

And, and when a lot of the cousins came down with prostate cancer,
and, and or lung cancer, or breast cancer, and my daughter had
breast cancer, I thought, well, maybe there's something that's in the,
In my genes.
If it was only that they probably wouldn't even recommend I get
tested, but I'm, I have I'm of Ashkenazi descent on my dad's side.
I actually tested first. She lives in Canada, and there's a bit of a
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different system.
Yeah, oh, yes. In fact, one of my, I have two sisters, one older, and
one about three years older, and one about 10 years younger. And
they had mild breast cancer. And both in the younger one got genetic
testing, and hers was all negative two for gene.
Family
characteristics
Closely related
family (children,
siblings)

I'm the only one left out in my family.

I have two older siblings, with my, my mom, and then I'm one of
seven on my father's side.
I have two children; one just turned 21. And one is 13.
Geographical
distance

Currently, they live in China. And, okay, that's not easy for them to
get that kind of test.

Requested referral
or HCP suggested

No, I had not considered it on my own. I really wasn't even aware
that it never crossed my mind to do this before. If there would have
been like breast cancer, that type of genetic type of cancers, then
maybe. But that I had none of that in my family.

Communication
with HCP or GC

I actually reached out I asked my breast surgeon, breast What?
Yeah, yeah, yeah. So I was diagnosed with breast cancer in 2017.
And I just knew that I wanted to get, you know, more information,
more data. And so that's when I asked her, and she referred me to
the genetic counselor there at the same hospital University.
I had to go to my primary care doctor, and then they sent me to like,
by a female doctor, and then I think it was the OB GYN who had to
like confirm, which I don't know how they confirm because it's still me
telling the same story.
Testing experience (From referral through results delivery)
Communication
with family
members
Family member’
I actually had my brother with me during one of my other brothers
involvement in
with me during all of this to make sure that we gave them the right
testing process (i.e., information.
support, physically
being presence)
Communication
with HCP
Had genetic
counselling

They took a family history, and then she kind of talked to me about
looking at, and my aunt she also had, I don't know, if it was uterine or
ovarian, I'm sure. But my grandmother and my father were better
than you. Yeah. And she also and then, yeah, my other aunt had
cancer. So we went through, like all the things, and she told me like,
what my risk was, and that we deal with the report. She was super
great. I forget who I went to, but she just told me, we're gonna do it,
we'll get the report. And then we'll figure it out.

Communication of
details regarding
test process

No, no, they asked me to go to the clinic here, lab test for lab tests,
then took some blood, and then I got the genetic test report.

Delivery of test
results (who, how)

They did the testing and then someone called me from the company
and like had this conversation with me that I really don't remember
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but I remember there was something prior but I did not have any
conversation with anyone after that I believe.
Recommendations Yep. So I will do I mean, she recommended some things and then
for screening or risk also the oncologist But you know, just going to the dermatologist
reduction
twice a year, getting your eyes checked, I will eventually get my
ovaries and fallopian tubes out. And just being kind of cognizant of
like pancreatic cancer, and what she had said the genetic counselor
had said that, you know, it's about a five to 10% higher risk. And if
you don't have any family history, they're not as concerned. And that
MD and that MD Anderson, I think is the only place that kind of…kind
of do that. She said that she has clients that use MD Anderson as
like a full test of whether you will get it but also my oncologist said
that they would just do screening, you know, once or twice a year for
that as well.
Recommendation
for family testing

He said right now it's probably not something they need to get tested
for but it's something that we need to keep an eye on to see what
develops with this gene and so that's kind of where it was left about
three years ago and i've not really had any conversations about it
since.

Cancer treatment
(i.e., impact on
memory, busy time
at start of treatment,
need to make
surgical decisions)

Like what happens next, because I was, like, fielding calls from
insurance companies, and then the surgeon in the hospital and then
the plastic surgeon, and it was just like too much, it was just too
much.

Other factors
affecting the
testing
experiences

Yeah, I feel my memory is reduced. And especially when I, when I'm
talking, it's likely you only can focus on for 10 minutes.
Delayed cancer
diagnosis

I first went to the, to my OBGyn, and she was like, well, you're young,
it doesn't seem like anything, it felt… like a cyst to be honest. And
even when I finally went back, like five months later, they still thought
it was related to nursing, but it had been so long that they wanted to
ultrasound it and that they knew immediately, like I knew, you know,
just looking at it, that it's probably cancer, because it had spread to a
few lymph nodes in the axilla.

Post-test experience
Feelings about
having a VUS

Surprise

I don't think you can be prepared. You can't be? No, because like I
said, intellectually, I knew, like, I look for those variants, that's what I
do for a living. But I don't think it would have changed anything
because it's either there or it isn't right. And at the time, I was sure
that I probably wouldn't have BRCA as like, Oh, it's fine. It's not going
to come nothing. It's going to be clean. They're just doing it for
whatever reason, right. But yes, I was surprised. I'm not gonna lie.
No, I wasn't surprised. I didn't really? I didn't know that there could be
a VUS. I thought it would either be positive or negative. Okay.

Curiosity

And so I really wanted to know about the genetics of cancer, because
I teach it in general biology to some degree, not, you know,
extensively, but I have a lecture on cancer where I talk about colon
cancer.
Curious as I don't think I fully understood what that variant meant,
and what impact it could have on my future.

Negative (stress,
anxiety, frustration)

A terrible, horrible, probably weeklong, stressful experience, because
I was like, Well, I didn't have any, you know, clarity so far. And then I
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was like reading about all these rare mutations. And I was like, Oh,
god, what if I have this thing that causes multiple types of cancers
and right syndrome? So then I was just like, you know, what, for my
own like, sanity, since it's not going to change, how I am sort of
operating with surveillance. And my daughter is nine. I'm not going
down that road. So I didn't.
So it for me personally, it was like, extremely nerve wracking, like
because it's, it's unknown.
Worry (for
themselves or their
family)

Am I going to be my sister very soon here?
I could have 15 VUS's, what worries me is that one or another
mutation causes my self to get some other form of cancer or my
daughter to get a cancer.

Positive/Relief

Uncertainty

I'm relieved, and I will tell you why. I'm relieved that it wasn't a
definite, like, the way it was explained to me is that this is kind of
nebulous, and it's indefinite, they will continue to test this gene, to
see if it's harmful or not. But at least there's no definite, hey, you
have BRCA Hey, you have this that will definitely or very likely cause
you cancer.
And it's, so you know, it's important to talk to them as well, like,
people need to know that. Just because they haven't found the gene,
that doesn't mean that the gene doesn't cause it, right. We just, we
don't know.
So I'm just in this very kind of state of I don't know if I'm saying
purgatory.
When you understand these things, you know, that it can be like, I
feel like a sitting duck, because I'm like, Well, what if it is pathogenic,
and you guys are doing nothing about it?

Recall and
understanding of
test result and its
implications
Recall of result and
implications

The genetic doctor called me to explain the results kind of tell me that
there was a little bit change in my genetic line. That's number one.
But I think it's not a big deal for me.

Understanding of
test result and
implications for
herself and their
family

You know, it seems to me to be one of those things that you don't
talk to your kids about, like sex and finances, you know, and I'm like,
but why, you know, I mean, it's, it's life, it's part of life.

PMS2 was, specifically when for men is common colon cancer. So,
but then, it may be maybe, maybe pancreatic cancer, slightly linked,
PMS2 is slightly linked with pancreatic. pancreatic cancer, also, you
see, our upper endoscopy type of testing, or, or maybe when I went
through colonoscopy.
Misunderstanding of But I guess for me, it kind of gave me a reason, right? I mean, so
the test result and its wasn't that I just sort of happened. You know, so that was helpful for
implication
me. It wasn't, I mean, I wasn't disappointed, or I didn't have any like
horrible feelings about it. And I think like I said, just for me, the
significance was that it just let me know why this might have
happened to me and things that I can do, kind of going forward to be
really on top of my health.
Impact of treatment
on recall
Remembers any

Like what happens next, because I was like fielding calls from
insurance companies, and then the surgeon in the hospital and then
the plastic surgeon, and it was just like too much, it was just too
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details of the VUS
much.
Personal
understanding of
meaning for self and
family
Recall of what was A panel of them of what? I don't think it was like a full genetic test
done
from what I remember.
...sent the sample in and it wasn't getting processed.
Coping
strategies used
Volunteerism

And I'm like, you know, when I saw this, I didn't know if I should,
because I'm still very anti engaging in anything cancer, because I
was still dealing with the, you know, the after effects, but I thought, if
I'm gonna encourage other people to be a part of these, I need to be
a part of this, because there's another woman who's probably been
told the exact same thing as me, who doesn't understand this either.
So I actually volunteer a lot for other young women with breast
cancer. And so I'm using sort of my VUS status to, and obviously,
my, my educational background, I guess, to sort of educate more,
and that's one of the reasons I wanted to participate in this is
because, you know, if, if my input can somehow help.

Information-seeking I don't think I had much of a hope or even expectation that was going
(episodic or
to happen anyway. I think that they thought I think they, meaning the
continual)
bioinformatics people at Fox Chase, thought that I was doing
something like that, but I really wasn't.
I have a friend of mine who's got, you know, really lots of family
history. And I'm like, have you done genetic testing? And he's like, I
don't want to know, I'm like, What? Yeah, really smart person, really,
you know, and he just doesn't want to know, and I'm like, wow.
Me and my husband went on to do research to make sure that we
knew what we were, you know, focusing on and what I needed to
worry about and what I didn't need to worry about.
Support groups

I found another…found a support group that I finally fit in for breast
cancer. It's an organization that is geared towards young women who
have most of the other support groups for like women who had
children by age, and none of them have small children. And these
women either have no children, or they have very young children.
Yeah, so I kind of feel like I found my tribe.

Personality

Roll with the punches with it, essentially.
As long as you're breathing, you've got more things going right for
you than wrong. So I'm good.

Communication
with family
members
Method of sharing
the result

My genetic counselor gave me a letter that I could send to them
which I've sent to them

Openness with
family

I'm not reporting on my gynecologist. That type of stuff. Yeah, for
sure. Yeah, definitely. Um, because it could potentially span the
whole family and affect, you know, all five of us, my parents, my
sister and my brother. So no, I emailed them. My genetic lab results,
my mom did the same. So you know, we have this like, family chain,
and that was definitely like, you know, take a look at this, consider it.
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Family wouldn’t
understand

And I also know that no one is going to remember everything of what
I say. So I have to tell more than one person, I have to seed it. Right,
make sure they have planted seed.
Oh, I didn't tell my brother or my father, because they just, like, can't
understand these things.

Concern for family

Of course, the genetic testing became important to me for that
reason, because of her, her well being because she had it on both
sides.
Now, if my results indicated it was hereditary, then I think I would go
back and pressure the grandkids a little bit.

Protecting family

My mom has had, like, it's very stressful for her. So my sister, my
sister and I were talking about it, and my sister was warning me she,
she saw the geneticist before me, and the geneticists originally
recommended that my mom have more testing. Before we did, and
my sister, you know, was warning me that mom's really worried that
means that she might have something and you have to tell her that
it's just for, for information for us. So my mom has a lot of anxiety
around it. But she's willing to talk about it. But yeah, we're treading
lightly.
I didn't know that I did not talk to my mother about my biopsies, which
is related but different. I did not talk to her about that because it was
just no, no, no, exactly. Especially when I got the results that they
were benign.

Family testing

My mother ended up with the exact same VUS and her sister ended
up with the exact same VUS.

The effects of the
communication (i.e.,
family members
testing- sharing of
new results)

So there's some distance between us we, I communicate with some
of them. When I was diagnosed with prostate cancer, I sent out a
message to all of my cousins and said, Hey, this may be hereditary,
make sure you get your PSA regularly and everything. And even
then, some of my male cousins didn't follow up on her now I have
now passed away because of prostate cancer.

Frustrations at
family’s response

A bit irritating that my dad's side of the family hasn't done anything.

Frustrations or
barriers

Most of your family physicians or general physicians, they don't go
through into these specific items. They are not...just not
knowledgeable enough to comment on it.

Racial bias

Then this was a team that really understood me. And they cared
about me. And I also it also made me think about physicians that I
choose, that are going to understand me, especially the bulk of the
health disparities that we see. Yeah. And I chose an African
American oncologist, I chose a woman breast surgeon, I chose
people that I knew what their client base look like, and that they were
open and diverse. Because you can't treat me like you treat someone
else with a different cancer.

Communication
with HCP (inc
GC)

Why would you tell me that? Like, why would you say you're clear,
but then tell me Oh, but there could still be cancer?
If you're my breast surgeon, you need to know what this means for
me, because I'm going to come in contact with you before I come in
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contact with a radiology oncologist or other oncologist.
Supports

And I can still just certain phraseology that she utilized, I was like, ah,
she knows what she's doing.

Keeping in touch/
Actually, no, I thought it went really well. I really liked my genetic
checking in with GC counselor, and I thought she was very open with me, and I was
happy with it. Okay. It's very helpful. I mean, she, she got my mom,
you know, she, my mom was able to contact her. And then she set
everything up for my mother. And my mom was in her 70s. So she
was very patient with my mom, as far as going through this process. I
really thought it went well.
Reclassification
communication

I'd have to, I don't know, one of them. I got like information that it had,
like moved from uncertain significance to likely not significant, but
likely benign, or, yeah, one of them.
And so that, that was and they might even recently, like got a note
that something had changed in my report. And I was scared that that
was going to turn into it was an unknown, and I was worried it was
gonna go the other way.

Risk reduction/
management
strategies used
Surgery

This past year has really kind of turned up the fire for me and it made
me honestly consider a preventative mastectomy.
So it worries me a little bit, but then I was so kind of caught up in the
emotion of, we need to get, I need to get rid of this. Like…what are
we doing next?
And I'm going no, I'm not looking to remove any more parts of me,
but because of a variant.

Follow-up visits

I see a provider so often, because I have either a mammogram or an
ultrasound every 6 months.
And now I have a GI doc right, so that I went out and searched for
those specialists and then share this information with them.
And I immediately burst into tears. And what was interesting about
that is, that's when I realized, ah, I've got some trauma here.

Cancer Screening

But other than that, no, and I'm not obsessing on it on a daily basis, I
really am not, but around appointment time I start rethinking about it,
or you know, breast cancer, or Breast Cancer Awareness Month in
February.
Yes, definitely MRI to answer your question. That is one of the things
that has been on the table, there has been some confusion about
coverage and how much that would cost.
It's not changing how I'm going to continue surveillance. Also, definitely not
going to change what I intend to do, you know, with my daughter way earlier
than myself, like, I started at 36 because of my mom's diagnosis, but like, I'd
love to start with my daughter, like, in her 20s, you know, so.

Further genetic testing

So fast forward then to 2018. That's when I had the second genetic test.
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Pretest Experience (Time Before Genetic Counseling or Genetic Testing Visit)
Category: Motivations/Reasons for Testing
This category includes the participant’s motivation, reason, and thoughts that led
to genetic testing. In addition to personal cancer diagnosis, family history of cancer and
suggestions from a HCP were the main reasons for participants to have genetic testing.
These motivations appeared to have influences on how the individual understands or
interprets the VUS for themselves.
Family History of Cancer
A family history of cancer was one of the reasons the individual had genetic
testing. Some participants had not had genetic testing even when they were diagnosed
with cancer but decided to get tested when other family members were also diagnosed
with cancer. Family history appeared to have an important role in how a person views
their risks; for instance, individuals tend to not worry as much about their risks of cancer
without a significant family history.
“I think, for me, it had more of an impact on what it was because my sister was
diagnosed 6 months after me.”
Some participants had a strong pattern of cancer in their family who were worried about
their cancer risks, even without a pathogenic variant being identified.
“So now I've got a father and two uncles with it and a couple of cousins, male
cousins with prostate cancer.”
This individual continued to collect data and encourage family members to take the family
pattern of cancer seriously.
When there was less of a pattern of cancer in the family or a known exposure
such as smoking, there was less concern.
“My mother's father had bone cancer, not really sure where it came from, but he
was a smoker. Okay. And that's all.”
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Personal History of Cancer
A personal history of cancer impacted the individual’s decision to have genetic
testing. Like family history, it also influences how an individual views their cancer risks
and the experiences in living with a VUS result. Individuals with cancers at a younger age
were also worried about their children’s risks and were motivated to learn the cause of
their cancer diagnosis. The first participant quoted is noting that the new screening
guidelines meant that his cancer was found later than it would have been if the screening
had been done more often.
“There's a lot of men that have prostate cancer and a lot of women that had breast
cancer that wasn't seen early enough, you know, so in my case, I have an
aggressive growth, and so it slaughtered me.”
The following participant was in the process of pursuing prophylactic surgery because of
her sister’s history of breast cancer, when she was also diagnosed with breast cancer.
“So about a month after the genetic testing results came back, I was supposed to
have my prophylactic mastectomy. But the last sonogram that they did, they found
breast cancer.”
Non-Cancer Diagnosis
One participant with a VUS result had an adrenal tumor and was referred for
genetic testing. He was found to have a VUS in a gene associated with cancer risk. This
participant described the surprising way he was informed of the finding of the tumor,
which at the time was not known to be benign. This tumor led him to have genetic testing.
The participant was informed of the mass in a way that created more uncertainty in his
subsequent medical care, including the genetic testing:
“And then she came in about an hour later. And it was actually kind of interesting
how she told me the first thing. I'm in Portland, Oregon, and I'm born and raised
here. And my whole family said, Do you have a good family network here and
support system? And immediately that kind of raised a red flag…And she kind of
kept going about that. And she's like, Yeah, we did find a growth in your abdomen
area. We don't can't say for sure what it is.”
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Concern for Family
Concern for family members, especially for children, was often mentioned as a
reason to have genetic testing. It also prompted discussions of cancer history and genetic
testing with family members.
“Both my mom and I had breast cancer, and I don't want my daughter to get
breast cancer. That's the only thing that I think about; that's all that matters.”
“I thought of my child, it wasn't really about me at that moment, like I need to do
what I need to do to be healthy to be here for her.”
HCP Recommended
In some cases, individuals both with and without cancer had not considered
genetic testing until a HCP suggested it.
“No, I had not considered it on my own. I really wasn't even aware that it never
crossed my mind to do this before. If there would have been like breast cancer,
that type of genetic type of cancers, then maybe but that had none of that in my
family?”
Category: Communication With Family Members
This category includes barriers, supports, and reasons leading to conversation
among family members during the pretesting process. Participants described the
communication about the family history collection or family member testing experience
and how their family characteristics affected their communication before they got tested.
Family Data Collection
Participants described the communication with family members in the pretest
period as mostly to gather family cancer history. Some noted that this was an ongoing
process, and they now get updates from their relatives as new cancers are diagnosed or
if they undergo genetic testing.
“… and when a lot of the cousins came down with prostate cancer, and, and/or
lung cancer, or breast cancer, and my daughter had breast cancer, I thought, well,
maybe there's something that's in the, in my genes.”
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Family Testing Status
Participants explained how the family members had been in contact around the
testing and test results to inform other family members who might benefit from this
information. In some cases, the participants were tested after a relative with or without
pathogenic results. In some cases, the participants were the first person tested in the
family and some other family members opted to get also tested after even with a VUS
test result.
In some cases, the participants were tested after a relative, for this person, it was
her mother. For some participants, the family members shared the same VUS; in others,
they do not.
“If it was only that they probably wouldn't even recommend I get tested, but I'm, I
have… I'm of Ashkenazi descent on my dad's side.”
The participant was the first person tested in some cases, even though a family member
had cancer first. This often was due to the lack of availability of genetic testing for the
family member.
“I actually tested first. She lives in Canada, and there's a bit of a different system.”
“Yeah, oh, yes. In fact, one of my… I have two sisters, one older, and one about
three years older, and one about 10 years younger. And they had mild breast
cancer. And both in the younger one got genetic testing, and hers was all negative
two for the gene.”
Category: Family Characteristics
Some participants noted that some family characteristics affected their
communication during the pretesting period. Closeness with a family member and
geographical distance were among the factors mentioned by the participant affecting their
decision to communicate as they were getting ready for testing.
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Closely Related Family (Children, Siblings)
Participants explained that closeness with a family member affected their decision
to communicate about the testing during the pretesting period.
Having close family members or children influenced the pursuit of genetic testing
and the participant's reaction to the result. Some participants came from large families
with many siblings:
“I have two older siblings, with my, my mom, and then I'm one of seven on my
father's side.”
Having children and their ages also influenced the reaction to a VUS, as adult children
were more likely to know about the test result or family history:
“I have two children, one just turned 21. And one is 13.”
One participant who did not communicate with anyone in the family noted, “I'm the only
one left out in my family,” which led her to not communicate before and even after the
genetic testing.
Geographical Distance
Geographical distance from family seems to play a role in communication with
family members during the pretesting process. The participants with relatives in other
countries may have discussed family history or genetic testing with their relatives, but
they were consulted less before genetic testing than those with relatives who were
physically closer. To facilitate timely action or recommended follow-up with those in the
family who need genetic counseling or even testing, some selected a physician or
scientist relative in the country as a point person to talk about the testing and even the
test result. Communication with relatives at a distance appeared to be a source of
frustration for participants.
“Currently, they live in China. And, okay, that's not easy for them to get that kind
of test.”
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Category: Communication With HCP or GC
Communication with a HCP pretest largely focused on the referral process. If the
participant had a new cancer diagnosis, the oncologist was usually the provider who
referred to genetics; sometimes, they ordered the test. If there was not a recent cancer
diagnosis, then a PCP or gynecologist may be the one ordering the referral.
Requested Referral
Pretesting process, communication with the HCP appeared to only include referral
or ordering the test. Although some participants stated that their HCP referred them due
to their personal or family history of cancer, some participants had to go through a long
and inconvenient process.
One participant pursued a genetics referral through multiple steps, when their
PCP referred them to a gynecologist, who then referred the participant to genetics:
“No, I had not considered it on my own. I really wasn't even aware that it never
crossed my mind to do this before. If there would have been like breast cancer,
that type of genetic type of cancers, then maybe. But that I had none of that in my
family.”
Another participant discussed asking their breast surgeon for the referral:
“I actually reached out I asked my breast surgeon... So I was diagnosed with
breast cancer in 2017. And I just knew that I wanted to get, you know, more
information, more data. And so that's when I asked her, and she referred me to
the genetic counselor there at the same hospital University.”
Requesting a referral was not always easy, and this participant had to go through multiple
providers before seeing genetics:
“I had to go to my primary care doctor, and then they sent me to like, by a female
doctor, and then I think it was the OB GYN who had to like confirm, which I don't
know how they confirm because it's still me telling the same story.”
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Testing Experience (From Referral Through Results Delivery)
Category: Communication With Family Members
Communication with family members during the testing process was mostly
centered around the participant getting emotional support.
Family Member Involvement in Testing Process (i.e., Support, Physically Being
Present)
Some participants had a family member or partner with them for the genetic
counseling and testing process, indicating a high level of openness. One participant
noted they want to have family with them to make sure they were understanding the
information correctly.
“I actually had my brother with me…during all of this to make sure that we gave
them the right information.”
Communication With HCP
During the testing period with genetic counselors or another provider, the key
points of the communication were how the results are delivered, how much details are
conveyed, and how recommendations were given for the participants and their family
members, and recommendations for family testing (if any).
Genetic Counseling Process
If a person had pretest counseling, what is included can also influence their
understanding and reaction to the VUS. Participants who recall being prepared for a VUS
were less surprised at the result.
“They took a family history, and then she kind of talked to me about looking at,
and my aunt she also had, I don't know, if it was uterine or ovarian, I'm sure. But
my grandmother and my father were better than you. Yeah. And she also and
then, yeah, my other aunt had cancer. So we went through, like all the things, and
she told me like, what my risk was, and that we deal with the report. She was
super great. I forget who I went to, but she just told me, we're gonna do it, we'll get
the report. And then we'll figure it out”
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Information Regarding Test Process
Communication of details about the test process includes information about
sample collection, how long the results take, and how they will be delivered.
“No, no, they asked me to go to the clinic here, lab test for lab tests, then took
some blood, and then I got the genetic test report.”
Delivery of Test Results (Who? How?)
How an individual was given their results may also influence their trust in
recommendations and their recall of the results. It was also important that the provider
delivering the results was knowledgeable about what they meant.
“They did the testing and then someone called me from the company and like had
this conversation with me that I really don't remember but I remember there was
something prior but I did not have any conversation with anyone after that I
believe.”
Recommendations for Screening or Risk Reduction
Some patients recalled the recommendations that had been made following
disclosure of the VUS. These ranged from routine screening for cancers to high-risk
screening. Surgical recommendations were made mostly for individuals with significant
personal or family histories of cancer and were not a direct result of the VUS. Some
individuals stated no recommendations were made, as the VUS was not informative.
“Yep. So I will do I mean, she recommended some things and then also the
oncologist But you know, just going to the dermatologist twice a year, getting your
eyes checked, I will eventually get my ovaries and fallopian tubes out. And just
being kind of cognizant of like pancreatic cancer, and what she had said the
genetic counselor had said that, you know, it's about a 5 to 10% higher risk. And if
you don't have any family history, they're not as concerned. And that MD and that
MD Anderson, I think is the only place that kind of do that. She said that she has
clients that use MD Anderson as like a full test of whether you will get it, but also
my oncologist said that they would just do screening, you know, once or twice a
year for that as well.”
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Recommendation for Family Testing
Most participants noted that no recommendation was made for family members to
test based on their VUS or history. Some did mention children who were eligible to testing
due to cancer history on the other parent’s side of the family.
“He said right now it's probably not something they need to get tested for but it's
something that we need to keep an eye on to see what develops with this gene
and so that's kind of where it was left about 3 years ago and I’ve not really had
any conversations about it since.”
Category: Other Factors Affecting the Testing Experiences
Other factors were noted to have affected the test experience, including cancer
treatment and the whirlwind time right after a cancer diagnosis.
Cancer Treatment (i.e., Impact on Memory, Busy Time at the Start of Treatment,
Need to Make Surgical Decisions)
Having genetic testing during cancer treatment had effects on the recall of the
genetic test information. Individuals who underwent genetic testing at the same time as
the start of their cancer treatment noted that it was difficult to recall the process of genetic
testing. This may be due to the “chemo brain” phenomenon, or it may also be that
individuals were too busy with treatment to process their reaction to the genetic test
result. Discussion of the VUS also brought memories of the emotional trauma associated
with the cancer diagnosis.
“Like what happens next, because I was, like, fielding calls from insurance
companies, and then the surgeon in the hospital and then the plastic surgeon, and
it was just like too much, it was just too much.”
“Yeah, I feel my memory is reduced. And especially when I, when I’m talking, it’s
likely you only can focus for 10 minutes.”
Delayed Cancer Diagnosis
A delayed cancer diagnosis was another factor impacting the experience of
having a VUS. It may have decreased the trust in medical providers.
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“I first went to the, to my OBGyn, and she was like, well, you’re young, it doesn’t
seem like anything, it felt…like a cyst to be honest. And even when I finally went
back, like 5 months later, they still thought it was related to nursing, but it had
been so long that they wanted to ultrasound it and that they knew immediately,
like I knew, you know, just looking at it, that it’s probably cancer, because it had
spread to a few lymph nodes in the axilla.”
Posttest Experience (From Right After Results Delivery Until Interview)
Category: Feelings About Having a VUS
Participants expressed several different feelings regarding having a VUS,
including surprise, curiosity, stress, anxiety, frustration, worry, relief, and uncertainty.,
Surprise
One participant was a geneticist and knew about the possibility of a VUS, but was
still surprised when she had this result.
“I don't think you can be prepared. You can't be? No, because like I said,
intellectually, I knew, like, I look for those variants, that's what I do for a living. But
I don't think it would have changed anything because it's either there or it isn't
right? And at the time, I was sure that I probably wouldn't have BRCA as like, Oh,
it's fine. It's not going to come to nothing. It's going to be clean. They're just doing
it for whatever reason, right? But yes, I was surprised. I'm not gonna lie.”
Another participant stated they expected a more definitive result.
“No, I wasn't surprised. I didn't really? I didn't know that there could be a VUS. I
thought it would either be positive or negative. Okay.”
Curiosity
Curiosity is the reaction of wanting to know how the VUS works or could impact
their life. One individual had both professional and personal curiosity about the VUS and
carcinogenesis, as they taught biology as biology teacher. This curiosity appears to keep
the participants continuously questioning the VUS result and its effect in his and his
children’s life.
“And so I really wanted to know about the genetics of cancer, because I teach it in
general biology to some degree, not, you know, extensively, but I have a lecture
on cancer where I talk about colon cancer.”
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Another person stated they were curious since they didn’t completely understand the
result.
“Curious as I don't think I fully understood what that variant meant, and what
impact it could have on my future.”
Negative (Stress, Anxiety, Frustration)
Negative emotions include stress, anxiety, or frustration. One participant had a
negative emotional reaction when considering expanding testing to a larger panel.
“A terrible, horrible, probably weeklong, stressful experience, because I was like,
Well, I didn't have any, you know, clarity so far. And then I was like reading about
all these rare mutations. And I was like, Oh, god, what if I have this thing that
causes multiple types of cancers and right syndrome? So then I was just like, you
know, what, for my own like, sanity, since it's not going to change, how I am sort
of operating with surveillance. And my daughter is 9. I'm not going down that road.
So I didn't.”
Cancer Worry (for Themselves or Their Family)
Cancer worry stemmed from not knowing if the VUS was pathogenic or benign.
Individuals who had cancer or a close family member with cancer were more worried.
“Am I going to be my sister very soon here?”
“I could have 15 VUSs, what worries me is that one or another mutation causes
myself to get some other form of cancer or my daughter to get a cancer.”
Positive/Relief
Despite the uncertainty of a VUS, a few participants still felt relieved that a
pathogenic mutation was not identified.
“I'm relieved, and I will tell you why. I'm relieved that it wasn't a definite, like, the
way it was explained to me is that this is kind of nebulous, and it's indefinite, they
will continue to test this gene, to see if it's harmful or not. But at least there's no
definite, Hey, you have BRCA. Hey, you have this that will definitely or very likely
cause you cancer.”
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Uncertainty
One participant felt it was important that individuals with a VUS understand that
there is still a possibility of a pathogenic variant that hasn’t yet been identified and that
the counseling process should help them understand this.
“And it's, so you know, it's important to talk to them as well, like, people need to
know that. Just because they haven't found the gene, that doesn't mean that the
gene doesn't cause it, right. We just, we don't know.”
“When you understand these things, you know, that it can be like, I feel like a
sitting duck, because I'm like, Well, what if it is pathogenic, and you guys are
doing nothing about it?”
“So, I'm just in this very kind of state of…I don't know if I'm saying purgatory?”
Category: Recall and Understanding of Test Result and Its Implications
Recall and understanding of the test result was another area which was important
to how a participant felt about the VUS. Additionally, the understanding of its implication
for themselves and their family was an important factor.
Recall of Result and Implications
Recall of the result and implications is what the person remembers about the
VUS. This is pure memory of what was the test result given to me, not interpretation or
understanding.
“The genetic doctor called me to explain the results kind of tell me that there was
a little bit of change in my genetic line. That's number one. But I think it's not a big
deal for me.”

Understanding of Test Result and Implications for Themself and Their
Family
Participants explained how they understood what a VUS meant to them in a
variety of ways. Some compared it to other aspects of life, while those with a science
education could describe in more detail what would happen if the VUS was pathogenic.
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“You know, it seems to me to be one of those things that you don't talk to your
kids about, like sex and finances, you know, and I'm like, but why?...you know, I
mean, it's, it's life…it's part of life.”
“PMS2 was, specifically when for men is common colon cancer. So, but then, it
may be, may be, may be pancreatic cancer, slightly linked, PMS2 is slightly linked
with pancreatic cancer, Also, you see, our upper endoscopy type of testing, or, or
maybe when I went through colonoscopy.”
Misunderstanding of the Test Result and Its Implication
Some individuals did not understand what the VUS meant for its implications on
cancer risk and screening. One participant felt the VUS explained her cancer diagnosis:
“But I guess for me, it kind of gave me a reason, right? I mean, so wasn't that it
just sort of happened. You know, so that was helpful for me. It wasn't, I mean, I
wasn't disappointed, or I didn't have any like horrible feelings about it. And I think
like I said, just for me, the significance was that it just let me know why this might
have happened to me and things that I can do, kind of going forward to be really
on top of my health.”

Recall of What Was Done
Recall of what type of test was done could be an indicator of overall recall of the
result. One participant does not recall as much about their test and does not differentiate
between MGPT and single gene sequencing.
“A panel of them of what? I don't think it was like a full genetic test from what I
remember.”
Another participant had tried to do the testing remotely a few times, and the GC needed
to facilitate their test as the sample kept failing.
“...sent the sample in and it wasn't getting processed.”
Category: Coping Strategies Used
Participants noted a few different coping strategies that helped them deal with
having a VUS. The most common were volunteerism and information-seeking.
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Volunteerism
Volunteerism was mentioned by a few individuals and seemed to be a coping
mechanism. One participant noted that they volunteered for the study to help others, and
it appeared it was a way of showing they are moving on.
Some individuals felt they could use their knowledge and experience with cancer
and genetic testing to help others in their age group with cancer.
“And I'm like, you know when I saw this, I didn't know if I should, because I'm still
very anti engaging in anything cancer, because I was still dealing with the, you
know, the after effects, but I thought, if I'm gonna encourage other people to be a
part of these, I need to be a part of this, because there's another woman who's
probably been told the exact same thing as me, who doesn't understand this
either.”
“So I actually volunteer a lot for other young women with breast cancer. And so
I'm using sort of my VUS status to, and obviously, my educational background, I
guess, to sort of educate more, and that's one of the reasons I wanted to
participate in this is because, you know, if, if my input can somehow help.”
Information-Seeking
Information-seeking includes doing research into what a VUS was and what it
means for cancer risk, including about what a pathogenic variant in the same gene would
mean. It also includes asking more questions from their HCPs.
“I don't think I had much of a hope or even expectation that was going to happen
anyway. I think that they thought I think they, meaning the bioinformatics people at
Fox Chase, thought that I was doing something like that, but I really wasn't.”
For some, information-seeking was such an important part of their personality that they
couldn’t understand anyone not wanting to know more.
“I have a friend… who's got, you know, really lots of family history. And I'm like,
have you done genetic testing? And he's like, I don't want to know, I'm like, What?
Yeah, really smart person, really, you know, and he just doesn't want to know, and
I'm like, wow.”
Some individuals sought knowledge as a team with their partner and used it to determine
what their level of concern should be.
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“Me and my husband went on to do research to make sure that we knew what we
were, you know, focusing on and what I needed to worry about and what I didn't
need to worry about.”
Support Groups
Although this individual is speaking about a cancer support group, it is an example
of what benefit these groups can provide. It also demonstrates the need for ageappropriate groups.
“I found another…found a support group that I finally fit in for breast cancer. It's
an organization that is geared towards young women who have most of the
other support groups for like women who had children my age, and none of them
have small children. And these women either have no children, or they have very
young children. Yeah, so I kind of feel like I found my tribe.”
Personality
A person’s view of adversity plays a significant role in their reaction to a VUS. One
person notes that both they and their family take a very fluid stance when dealing with
adverse or uncertain events.
“Roll with the punches with it, essentially.”
Other individuals were optimistic and felt that being alive itself was enough, so they were
not bothered by uncertainty.
“As long as you're breathing, you've got more things going right for you than
wrong. So I'm good.”
Category: Communication With Family Members
Communication with family members in the posttest period included sharing of
test results, discussion of recommendations, family testing, and further discussions about
family history. This category also includes codes pertaining to the reactions or feelings
about family communication, such as the family not being able to understand, concern for
family, protecting certain family members from the information, and frustration with the
family’s response.

59

Method of Sharing the Result
This participant noted the genetic counselor provided them with a letter for their
family. Others noted using verbal and electronic communication methods.
“My genetic counselor gave me a letter that I could send to them which I've sent to
them.”
Openness With Family
A previous history of being open about medical information was important to
communicate with family members. This participant describes sharing the test results
through email and having discussions with family members, encouraging them to test.
“I'm not reporting on my gynecologist. That type of stuff. Yeah, for sure. Yeah,
definitely. Um, because it could potentially span the whole family and affect, you
know, all five of us, my parents, my sister and my brother. So no, I emailed them.
My genetic lab results, my mom did the same. So you know, we have this like,
family chain, and that was definitely like, you know, take a look at this, consider it.”
Family Wouldn’t Understand
A family member is less likely to be informed of the VUS if the participant didn’t
think they would understand the information. Interestingly, if a person was thought to not
be able to understand the genetic test information, it was usually a male family member.
It was unclear if the concern was with comprehending a VUS or understanding a
potentially higher risk of “female” cancers.
“And I also know that no one is going to remember everything of what I say. So I
have to tell more than one person, I have to seed it. Right, make sure they have
planted a seed.”
“Oh, I didn't tell my brother or my father, because they just, like, can't understand
these things.”
Concern for Family
A motivation for communication with family about the VUS was a concern for their
health.
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“Of course, the genetic testing became important to me for that reason, because
of her, her well-being because she had it on both sides.”
“Now, if my results indicated it was hereditary, then I think I would go back and
pressure the grandkids a little bit.”
Protecting Family
One participant described a need to protect her mother from knowing she had
biopsies, because she didn’t want her to worry unnecessarily. Her mother had been very
stressed by a sister’s cancer diagnosis.
“I didn't know that I did not talk to my mother about my biopsies, which is related
but different. I did not talk to her about that because it was just no, no, no, exactly.
Especially when I got the results that they were benign.”
Although in this case the participant is protecting her mom from worrying about a possible
cancer diagnosis, the same mechanism can lead to an individual protecting a family
member from worrying about a VUS. Another participant describes being very careful
about discussing genetic testing around their mother, as it was causing the mother
increased stress.
“My mom has had, like, it's very stressful for her. So my sister, my sister and I
were talking about it, and my sister was warning me she, she saw the geneticist
before me, and the geneticists originally recommended that my mom have more
testing. Before we did, and my sister, you know, was warning me that mom's
really worried that means that she might have something and you have to tell her
that it's just for, for information for us. So my mom has a lot of anxiety around it.
But she's willing to talk about it. But yeah, we're treading lightly.”
The Effects of the Communication (i.e., Family Members Testing/Sharing of New
Results)
Some participants noted that family members got genetic testing or cancer
screening because of their discussions about the family history and the VUS, while others
noted that nothing happened as a result. Sometimes barriers existed (such as not having
access to care), while other times no behavior change was needed.
“So there's some distance between us. We…I communicate with some of them.
When I was diagnosed with prostate cancer, I sent out a message to all of my
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cousins and said, Hey, this may be hereditary, make sure you get your PSA
regularly and everything. And even then, some of my male cousins didn't follow up
on her; now they have passed away because of prostate cancer.”
Family Testing
Family members testing, either as part of a reclassification study or a separate
genetic test, was one outcome of communication.
“My mother ended up with the exact same VUS and her sister ended up with the
exact same VUS.”
Frustrations at Family’s Response
A few patients were confused and frustrated with family members who did not act
on the family history. One saw new cancer diagnosis in the family as a result of this
inaction.
“A bit irritating that my dad's side of the family hasn't done anything.”
Category: Communication With HCP (Including GC)
Communication with HCPs posttest includes both frustrations or barriers and
supports. Other codes in this category include keeping in touch with the genetic
counselor, reclassification communication, risk management strategies, surgery, followup visits, cancer screening, and further genetic testing.
Frustrations or Barriers
Frustrations or barriers to good communication with HCPs include feeling that the
provider was rushed, lack of provider knowledge, and unclear communication.
The perception of PCPs as not having knowledge about genetics, especially a
VUS, was common:
“Most of your family physicians or general physicians, they don't go through into
these specific items. They are just not knowledgeable enough to comment on it.”
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Another individual was frustrated that her provider had said the VUS doesn’t
mean anything, but then said there was still a chance it was pathogenic:
“Why would you tell me that? Like, why would you say you're clear, but then tell
me ‘Oh, but there could still be cancer?’”
Finally, a participant noted her frustration that her breast surgeon gave her the
wrong information about the VUS:
“If you're my breast surgeon, you need to know what this means for me, because
I'm going to come in contact with you before I come in contact with a radiology
oncologist or other oncologist.”
Racial Bias
At least one woman noted she felt that because she’s a Black woman, the
physician wouldn’t listen to her and just told her what to do, and that the oncologist
recommended an aggressive course of treatment based on the VUS. She switched her
care to a new team and described how it made her feel more comfortable with her care.
“Then this was a team that really understood me. And they cared about me. And I
also… it also made me think about physicians that I choose, that are going to
understand me, especially the bulk of the health disparities that we see. Yeah.
And I chose an African American oncologist, I chose a woman breast surgeon, I
chose people that I knew what their client base looks like, and that they were
open and diverse. Because you can't treat me like you treat someone else with a
different cancer.”
Supports
Factors that support good communication with HCPs include clear communication
and providers appearing knowledgeable. This participant felt that the way the genetic
counselor communicated implied a high level of knowledge:
“And I can still just hear certain phraseology that she utilized, I was like, ah, she
knows what she's doing.”
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Keeping in Touch/Checking in With GC
A few participants had called their GC to update family histories, check in on
reclassification, or to discuss further testing. These individuals felt the GC was
approachable regarding check-ins.
“Actually, no, I thought it went really well. I really liked my genetic counselor, and I
thought she was very open with me and I was happy with it. Okay. It's very
helpful. I mean, she, she got my mom, you know, she, my mom was able to
contact her. And then she set everything up for my mother. And my mom was in
her 70s. So she was very patient with my mom, as far as going through this
process. I really thought it went well.”
Reclassification Communication
Almost all the individuals knew about reclassification as a possibility, but only a
few had a reclassified VUS. One participant described receiving the information:
“I'd have to, I don't know, one of them. I got like information that it had, like moved
from uncertain significance to likely not significant, but likely benign, or, yeah, one
of them.”
Another noted that when she was notified of the reclassification, she was worried the
VUS had become pathogenic.
“And so that, that was, and they might even recently… like get a note that
something had changed in my report. And I was scared that that was going to turn
into an unknown, and I was worried it was gonna go the other way.”
Category: Risk Reduction/Management Strategies Used
Risk reduction or risk management strategies include surgery, follow-up, cancer
screening, and further genetic testing.
Surgery
Individuals with a personal or family history may consider surgery, and
occasionally the added uncertainty of a VUS influences that decision. One person
discussed their increased anxiety when screening over the past year, and therefore is
considering prophylactic surgery.
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“This past year has really kind of turned up the fire for me, and it made me
honestly consider a preventative mastectomy.”
Others described a need to remove the body parts that are cause for concern:
“So it worries me a little bit, but then I was so kind of caught up in the emotion of,
we need to get, I need to get rid of this. Like…what are we doing next?
Others did not want to have prophylactic surgery, given the inherent uncertainty of the
VUS.
“And I'm going no, I'm not looking to remove any more parts of me, but because of
a variant.”
Follow-Up Visits
Some of the participants noted that they were getting screened often, due either
to a personal or family history of cancer that made them high risk.
“I see a provider so often, because I have either a mammogram or an ultrasound
every 6 months.”
Some participants hand-picked a specialist who they liked, who would do their cancer
screenings.
“And now I have a GI doc right, so that I went out and searched for those
specialists and then share this information with them.”
Others noted that follow-up was associated with their cancer diagnosis, and therefore
caused them to remember the negative emotions from that time of their lives.
“And I immediately burst into tears. And what was interesting about that is, that's
when I realized, Ah, I've got some trauma here.”
Follow-up also caused some individuals to think about their genetic test result.
“But other than that, no, and I'm not obsessing on it on a daily basis, I really am
not, but around appointment time I start rethinking about it, or you know, breast
cancer, or Breast Cancer Awareness Month in February.”
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Cancer Screening
Some individuals were considering high-risk screening, such as with breast MRI.
Insurance coverage for these screenings without a pathogenic variant was a point of
confusion for both the individuals and their healthcare providers.
“Yes, definitely MRI to answer your question. That is one of the things that has
been on the table, there has been some confusion about coverage and how much
that would cost.”
Others noted that having a VUS didn’t alter their screening plans. In some cases,
participants were satisfied with continuing the average-risk screening. Others, like the
individual quoted below, wanted to pursue higher risk surveillance.
“It's not changing how I'm going to continue surveillance. Also, definitely not going
to change what I intend to do, you know, with my daughter way earlier than
myself, like, I started at 36 because of my mom's diagnosis, but like, I'd love to
start with my daughter, like, in her 20s, you know, so.”
Further Genetic Testing
One participant had their initial genetic testing to a larger panel. Another had
additional genetic testing, which identified a clotting disorder.
“So fast forward then to 2018. That's when I had the second test genetic test.”
Moving From Findings to Theory

The findings of these interviews provide a rich description of living with a VUS.
The participants describe the varied emotions they experienced after learning of their
result, and the ways in which they cope with the uncertainty. They described the context in
which the VUS is experienced, which cannot be uncoupled from the experience. The
findings also describe the key processes that the participants viewed as part of their VUS,
and their needs as they continue to live with this uncertain result. These findings set the
course to develop a theoretical model to describe the experience of having a VUS, which
is described in the remainder of this chapter.
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Proposed Theory of Living With a VUS Result for Cancer
What Is the Experience of a VUS?
A VUS result is a genetic test result that carries a high level of uncertainty. How
individuals make meaning of it is based on multiple factors, including their personal
characteristics, coping mechanisms, and cancer experiences. Communication with family
and healthcare providers play key roles in the experience of testing and living with a VUS
result that brings so much uncertainty for them and their family members (See Figure
4.1).

Contextual factors
Demographics
Personality
Coping strategies

Communicating with
healthcare providers

Family characteristics

Decisions

Family dynamics
Cancer history
Cancer diagnosis

Communicating with
family

Life with a VUS

Needs:
Knowledgeable
and trustworthy
providers

Support for
emotional needs

Open lines of
communication

Figure 4.1: A theoretical model of the experiences and needs of individuals with a VUS.
Cancer itself is a distressing diagnosis to receive, and having genetic testing right
after a cancer diagnosis appears to be distressing and making things even harder to cope
with. The cancer treatment itself was described by the participants as causing cognitive
impairment, and individuals discussed the trauma associated with that time period. The
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stress of that time makes it difficult to process the results of the testing or recall what they
were told. Experiences during the cancer diagnosis also affect the subsequent perception
of genetic testing and living with a VUS result. For instance, a delay in diagnosis impairs
individuals’ trust in their HCP, and the participants who described a delayed diagnosis
also were more anxious about the possibility that a VUS would be pathogenic.
Context
Understanding the context in which an individual experiences genetic testing and
living with a VUS is crucial to understanding the overall experience that ultimately helps
the healthcare provider find better ways to serve these individuals. Contextual factors
include sociodemographics, personality characteristics, coping strategies, family
characteristics, cancer history, cancer diagnosis, and cancer treatment.
Education may play an important role in the understanding of a VUS result and
experience in living with the result. Having a science background gives a participant more
ability to understand genetics concepts and also a VUS. However, it may also give more
curiosity and continuous motivation to search the implications of a VUS result. Having
higher levels of education, even in non-science fields, still provided a greater
understanding of how to research the VUS.
Insurance coverage has a role both in genetic testing and subsequent
experiences. Participants noted that their insurance covered the genetic testing or they
were able to pay out of pocket for the test. Later, some had confusion or problems with
getting their insurance to cover cancer screenings such as breast MRI. Others were
denied coverage from their insurance for second or third rounds of genetic testing.
Geographic location affected the overall testing process. Some individuals had to
drive to other cities to have genetic counseling and testing. Others noted that they felt
lucky to live in a city with a large medical center where they could easily access all the
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healthcare they needed. Geography was also relevant for family communication, as it
influenced how the participants shared results with their family, and how useful they
thought the information would be. For instance, if relatives were in the United States or
Canada, it was expected that they could get cancer screening and genetic testing if
needed. If the relatives lived in China or India, it was expected that getting screened
would be much harder, and that genetic testing was essentially impossible. In these
cases, the VUS and family histories were still discussed, but the participants didn’t press
their relatives as hard to pursue cancer screening.
Personality characteristics are also an important factor impacting the ability to live
with uncertainty. Some participants tended not to worry about things that are out of their
control, while others found that lack of control to be very stressful. These perceptions of
uncertainty influenced their feelings about the VUS. Some participants were not bothered
by having a VUS result due to its lack of effect on their lives when compared to a major
life event such as cancer, while others emphasized that they just simply are not bothered
by events that are outside their control, or that are not definitely a threat to their health.
Individuals who were more anxious about the VUS tended to not be comfortable with
uncertainty and preferred to be able to make plans to control outcomes.
Individuals described different coping mechanisms that affected their overall
experience during and after the testing. Some individuals pursued information-seeking to
feel more proactive toward cancer prevention and early detection; others chose to learn
more about the gene itself and the mechanisms of cancer. Individuals who employed
information-seeking likely were using this process to gain a sense of control over their
health, as were individuals who felt more comfortable with pursuing high-risk cancer
screening or prophylactic surgeries.
Family characteristics were important. Family members were not only someone to
communicate test results to but also were sources of support. Emotional closeness
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provided this support and created a more open environment in which to talk about genetic
testing and cancer risk. The demographics of the family members such as educational
level, sex, or current place of residency were also important. Female relatives were
considered more at risk for breast cancer and therefore more likely informed if there was
thought to be a risk for breast cancer, while male relatives were informed of prostate
cancer risk. The education level of the family members, as well as their ability to
understand the genetic information was also important, as relatives who were physicians
or scientists were often treated as the first point of contact.
Individuals who had cancer themselves and a family of history of cancer were
more concerned that it will be discovered that their VUS is pathogenic, or that there was
some other hereditary cause not yet found. Those who noted cancers only in older
relatives or were the only person in their family with cancer were not as concerned about
the chance of a hereditary risk. Similarly, if the gene were the VUS was identified was not
associated with the pattern of cancers in the family (i.e., A VUS in PMS2 but the family
history is of breast cancer), then the VUS was not as concerning.
Communication With Healthcare Providers
Communication with healthcare providers is a key component of the experience in
both genetic testing and having a VUS result. This communication involves the decision
to get tested, preparation for testing, results disclosure, and how they are advised of the
implications of the test results such as cancer screening, preventive surgeries, family
members need to be tested. In the longer term, this communication occurs during followup, when updating their personal or family history, and when learning about any
reclassification of the VUS.
Communication with healthcare providers affects all experiences around having a
VUS result and appears more complicated than for those individuals with a more
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definitive genetic test result. Participants described healthcare providers who appeared
uninformed as to what a VUS was, and what the implications were. They noted getting
conflicting advice on cancer screening and prophylactic surgeries from different
healthcare providers. Other participants, who described their healthcare providers as
knowledgeable, noted that they were given clear guidelines on what the implications of
the VUS were. Having incorrect or inconsistent information about the VUS and
management recommendations decreases the individual’s trust in their providers.
Considering the nature of a VUS result and lack of guidelines in the management of
these cases, it is important to make clear that the limitations are with the science of
genetic testing, and not the provider.
Participants were more comfortable with healthcare providers they perceived as
knowledgeable and trustworthy sources of information. If the HCP was seen as
untrustworthy or not knowledgeable due to confusing communications, then the
participant did not trust their recommendations and had more anxiety or worry. When an
individual received incorrect or inconsistent information about the VUS from their
provider, this reduced the trust in that provider
Racial and gender issues were mentioned in the communication with HCPs. One
participant, a younger Black woman, noted she felt that her first oncologist didn't listen to
her needs or questions about her genetic test and what was needed for her breast cancer
treatment. She noted that this physician was an older white man who did not give her
options. After experiencing severe complications from an aggressive treatment approach,
she decided to transfer to an oncologist she selected, a younger Black woman, who she
felt gave her more options and supported the choices she made. She felt that she had
been dictated care because she was a young, Black, woman, and that had led to her
complications. Her trust in the system had been ruined, and her new care team had to
rebuild it.
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Good communication is supported when the provider clearly communicates with
the patient and is confident in their recommendations, which leads to the patient feeling
more comfortable. There were several times when participants noted that a provider
appeared to be uncertain in what they were saying, and each of these times the provider
was not a specialist in genetics. In contrast, the times where participants stated they felt
like they were speaking to an expert, it was a genetic counselor who they were
communicating with. One participant even noted that the way the GC spoke made them
feel comfortable that they were speaking with an expert. This highlights the need for
providers to not only be knowledgeable but also to be confident in their communication of
that knowledge. Geneticists or genetic counselors gave the clearest explanations of
recommendations, preparing participants for possible results including a VUS, and
generally were described as more knowledgeable.
Self-advocacy supported good communication with healthcare providers. This
occurred when participants spoke up for themselves and their needs, as providers were
seen as rushed or not knowledgeable enough to provide the necessary care. Individuals
described asking for specific referrals and tests, and those who didn’t expect a provider to
be entirely knowledgeable about the VUS seemed more satisfied that they were getting
the care they need. Additionally, participants who were able to select the providers they
saw for follow-up were much happier with their care.
Finally, the participants stated that they appreciated the follow-up invitation from
the healthcare provider who had done their genetic testing; usually this was from a
genetic counselor. Some had the opportunity to update their family history with the
provider or were involved in helping their family members to be tested. Some only
checked in about the status of the VUS, or with questions about medical management. A
few participants emphasized the importance of updating the contact information of
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patients on a regular basis, to ensure that they receive any news on the reclassification of
the VUS result. An alternative suggestion was scheduling a routine follow-up.
Decisions
Decision-making started when participants either sought referral for genetic
testing or were recommended to have genetic testing by a provider. Reasons for this
decision included determining cancer risks, concern for family, and to support treatment
and surgical decisions. Most participants described the frustration with decisions after
receiving a VUS test result, including cancer screening, preventive surgery, follow-up
visits, and their children's healthcare. Most of the healthcare decisions made were not
directly a result of the VUS, but were complicated by the uncertainty or lack of clear
guidelines for individuals with a VUS. Some participants described having multiple rounds
of genetic testing, due to the need for expanding an initial small gene panel to a larger
one. Most accepted further testing; however, one participant chose not to have a third
round as the thought of another VUS was causing her too much anxiety.
Cancer screening pursued by participants included mammography, breast
ultrasound and MRI, pelvic ultrasound, colonoscopy, and PSA. Many participants were
still considered high risk due to their personal or family histories of cancer and were
instructed to follow high-risk cancer guidelines, including increased frequency and
different modalities of screening. Participants who were currently too young to pursue
cancer screening noted that they needed to consider it in the coming years. Of note, a
few patients insisted on high-risk screening, regardless of what their guidelines or their
provider suggested. The decision to pursue high-risk screening appeared to be a coping
mechanism, as it allowed them some semblance of control over an uncertain situation.
Surgical decisions include methods used to treat or remove a known cancer, as
well as prophylactic surgery, specifically mastectomy or oophorectomy. In some cases,
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the VUS result was used to support the decision for a mastectomy instead of more
conservative surgery. Some women were in the process of deciding on a prophylactic
mastectomy due to their family history, even though no genetic risk for cancer had been
identified. Other women discussed considering surgery in the future when they are past
menopause, and still others were not interested in surgery at all unless a genetic risk was
identified. Participants were not clear on if their treatments would have been different had
a pathogenic result been identified (i.e., the selection of a PARP inhibitor for breast or
prostate cancers).
Deciding when to tell a child about the family history of cancer and the VUS was
another part of the experience affecting life of individuals with a VUS result. Although
participants with younger children appeared not to keep their cancer diagnosis hidden,
they tended not to discuss the VUS or potential familial risks with their children. Some
participants who had older children had informed them about the test result and
encouraged their children to pursue more cancer screening. Others did not try to
influence their children’s decisions, or said they would only if an actual hereditary risk was
identified.
The decision to continue to follow up with a HCP often was a precursor to other
decisions to make. For instance, some participants changed their providers or delayed
care to see a specific provider to feel more comfortable. Sometimes suggestions that
were made at these follow-up visits led to more decisions about genetic testing or
screening.
Family Communication
Family communication was both a way of seeking support as well as discussing
medical history. It is vital for individuals with personal and family histories of cancer to
share this information. Participants in this study frequently noted that finding out about a
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family history of cancer started them on their own genetic testing journey. One participant
even had her cancer found because of pursuing prophylactic mastectomy after learning
about her sister’s breast cancer diagnosis. Some of the influences we identified were
emotional and relational closeness, perceived importance of the information, a risk to the
family member, and openness. Barriers included perceived inability to understand
information, a need to protect the family from negative or confusing information, a lack of
relatives to discuss the information with, and geographical location or distance.
Emotional and relational closeness was important for communication with family
members. Distant relations and those who are not emotionally close were not always
informed about the genetic test results. Mothers and sisters were most likely to know
about the VUS, especially if the participant was a woman and if breast cancer was part of
the family history. In some cases, closeness led to a need to protect the family member
from the stress knowing about the VUS might bring, such as cases where information
was kept from a parent or child.
Openness was also important. Many participants who had shared their genetic
test results were also open about other aspects of their health. Openness also included
having a sibling or partner participate in the counseling visits. In these cases, the
communication was not just about making sure information was conveyed, but it also
provided support for the person being tested.
Partners were often not only informed of the VUS but were also part of the
counseling visits. This was especially true if the participant was going through cancer
treatment at the time of the genetic test. If the participant had children, their partner was
part of the discussion on when or how to inform them about the family history. Partners
were also cited as helping with researching information about the VUS.
Not having any closely related family was one reason someone may have not
communicated with family about their test results. Close relatives were noted to be
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children, siblings, and parents. Sometimes this was extended to aunts or uncles, cousins,
and nieces or nephews. When some individuals had only elderly family or distant cousins,
they didn’t always communicate the results.
Another reason not to share their results or history was due to a perceived
inability of the family member to understand the results. This was not clear whether they
meant the person couldn't understand cancer-related health issues, genetics, or both. It
may also be an emotional inability to cope with the uncertainty. Male relatives were more
often noted to be unable to handle the information.
As mentioned previously, the geographical distance was a barrier. First, relatives
in a different country were frequently informed through email or phone calls and not in
person. Second, many noted they weren't sure the information would be helpful since
genetic testing wasn't widely available in the country where their relatives resided.
The perceived importance of the VUS or family history was also key. For instance,
if the gene is associated with breast cancer, it is more likely that a female relative will be
told, but a male relative might not because of a belief that the genetic information
wouldn’t impact them. It was less likely to be shared if the test result wasn’t viewed as
important to someone’s medical care.
Needs
Participants noted a need to get their healthcare from a knowledgeable and
trustworthy provider. This person does not need to be an expert in genetics. However,
they do need to understand the basics of genetic testing for hereditary cancer, how family
history impacts cancer risks, and where to seek information when they don't know
enough about a given topic. This could be in consultation with an expert or referral to
genetics. Participants were appreciative that sometimes the provider needed to do
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research before giving them advice. Honesty that the uncertainty of the VUS is a
limitation of the current science was also important.
Individuals also needed open lines of communication with their healthcare
providers. Patients should feel able to recontact their provider about reclassification,
family history changes, or to ask new questions. Some participants appeared to be
curious about the new discoveries on the VUS result and interested in learning more
about what a VUS result meant for them or their family members. Some were interested
in learning more about their children’s risks. Life circumstances might also prompt the
need for more information such as deciding to have children or children becoming adults.
Most participants appreciated when they were given the option to keep in touch with their
provider.
Finally, participants needed to have their emotional needs supported. This support
can occur at any time but is needed particularly during the pretest decision-making and
when the results are delivered. These needs varied among participants, from preparation
for genetic test outcomes, to identifying those with higher levels of stress and anxiety
after learning about the VUS. Active coping, such as joining support groups or
volunteering, was often noted to be a successful way of reducing negative emotions.
Other participants appreciated when providers recognized that information-seeking was
their way of coping and therefore continued to answer questions or assist them in
identifying resources.
Summary/Conclusion
This qualitative, grounded theory study describes the experiences of individuals
with a VUS on genetic testing for hereditary cancer risk. We found that many contextual
factors, including cancer diagnosis, family history, personality traits, coping mechanisms,
and having close relatives influence the key process of communicating with family,
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communicating with healthcare providers, and decision-making. The major needs of
individuals with a VUS were knowledgeable and trustworthy providers, open
communication with healthcare providers, and support for their varying emotional needs.
This study shows that the experiences of the individual with a VUS are much more
heterogeneous than previously understood and are heavily reliant on the context in which
the person learns about and lives with the VUS.
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CHAPTER 5
DISCUSSION
The purpose of this grounded theory study was to describe the experiences of
individuals with a VUS on genetic testing for hereditary cancer risks. Despite the
increased use of multigene testing for hereditary cancer risks and its subsequent
increase in the numbers of identified individuals with a VUS, very little is known about the
experiences of these individuals. Therefore, it is vital to understand how individuals live
with a VUS result and how these individuals can be best supported. We used
constructivist grounded theory methods to achieve this purpose. A semistructured
interview guide was developed based on the review of literature and past experience, and
a total of 20 interviews were conducted. After transcription, several rounds of coding were
completed according to Charmaz and Saldaña (Charmaz, 2014; Saldaña, 2021; Vanover
et al., 2021) until a satisfactory theoretical framework was developed.
First, this chapter will attempt to answer each research question using the
collected data and emerging model of the study, as well as the related literature. Next, we
will review the theoretical model, and make recommendations for future research and
clinical practice. Finally, we will present the limitations of this study.
Research Questions
To review, this study focused on answering three primary research questions:
1. What does having a VUS result for hereditary cancer susceptibility mean to
individuals for themselves and for their first-degree relatives?
2. What is the experience of individuals with a VUS result for hereditary cancer
susceptibility in communication with healthcare professionals?
3. What is the experience of individuals with a VUS result for hereditary cancer
susceptibility in communication with family members?
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We will next discuss the findings as they relate to each individual question.
Meaning of Having a VUS Result for Hereditary Cancer Susceptibility for
Individuals for Themselves and Their First-Degree Relatives
The results of this study show that the experience of a VUS is highly
individualized and contextual. Some of the most important factors that influence this
experience are personal and family history of cancer, individual coping mechanisms and
personality, and communication with healthcare providers. Having children or other
closely related family members also influences the experience of a VUS. A VUS is often
described in terms of an individual’s personal interpretation of its associated cancer risks.
Additionally, the process of decision-making is central to the experience of a VUS, as the
individual decides on healthcare such as testing and risk-reduction strategies, who to
communicate with, and how they will do this. In the literature, it was also found that it
individual characteristics, and not the type of hereditary cancer syndrome, that caused
differences in psychological distress and coping (van Oostrom et al., 2007).
In this study, participants weren’t always able to state what gene the VUS was in;
however, they generally understood that it was not a result that changed their medical
management, and that it did not mean they had a hereditary predisposition to cancer.
Moreover, a difference existed between recall and personal interpretation of the VUS.
Although none of our participants stated they believed they had a hereditary cancer risk,
several were concerned due to the combination of histories and the VUS. Few studies in
the literature focus on individuals with a VUS result, and these studies focus mainly on
knowledge, understanding, and recall of the test result. Giri et al (2018) examined health
literacy as an explanation for a lack of understanding but didn’t find an association. Other
studies also found confusion about what a VUS was (J. G. Hamilton et al., 2019; Tsai et
al., 2020). Studies examining knowledge found that while some individuals do have a
basic knowledge of genetics, it isn’t comprehensive, and most people have no knowledge
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about it (Veilleux et al., 2020). Peterson et al. (2018) reported that better genetics
knowledge is associated with having higher educational attainment, income, and
numeracy skills; being female, a nonsmoker, white, and married; and having a family
history of cancer. Reuter et al. (2019) similarly found that recall was better than the
understanding of etiology. These findings show that individuals with a VUS result may
recall and know that they had a VUS result; however, it may bring many unknowns
related to how to use this information for themselves and their families.
A majority of our study participants had a college degree or higher; therefore,
compared to the general population, they may have been more likely to have some prior
knowledge of genetics. Bartley et al. (2020) found that higher genomic literacy allowed
individuals to make more meaning from the VUS. Therefore, it is possible that our
population had an experience different from the general population with a VUS.
Consideration of genomic literacy and overall education should be included in pretest
counseling.
This study describes the importance of context in personal understanding of a
VUS, with cancer history and personal characteristics playing an important role. Vos et al.
(2008) found that understanding of the VUS was influenced by how it was explained in
the context of family history. Reuter et al. (2019) noted that the appraisal of the VUS was
done based on the personal and family pattern of cancer. This supports a consideration
of context when discussing genetic testing and is an area that needs future research.
We found that individuals with a VUS experienced different emotional reactions,
with some participants noting relief that the result was not pathogenic, and others being
anxious about the uncertainty and worried about cancer risks. This is consistent with the
limited literature, where it was found that individuals with a VUS did have distress related
to the result, but many had a decrease in distress or were less distressed than those with
a pathogenic variant (Culver et al., 2013; Esteban et al., 2018; Richter et al., 2013). Some
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participants, in this study, had various emotional responses including anxiety, worry,
neutral, surprise, and relief. Many participants didn’t think about the VUS very often.
Although Tsai et al. (2020) found that anxiety was related to a misunderstanding of the
VUS, in this study anxiety was more related to the uncertainty. Participants in this study
who were more comfortable with uncertainty tended not to worry as much about the VUS.
While some studies have examined individuals’ ability to deal with uncertainty in cancer
or genetics (Bartley et al., 2020; Braithwaite et al., 2002; Wonghongkul et al., 2000), most
other studies examining emotions about a VUS focused on psychological impact and
found either no or low levels of distress after having genetic testing (Peterson et al.,
2018). Fear or distress of the unknown can increase negative reactions to a VUS
(Carleton, 2016). Although comfort with uncertainty is not a trait that is easily influenced,
it is something that should be assessed during the pretest visit.
In this study, we also found that active coping was often employed successfully to
manage the uncertainty of a VUS. These coping strategies included information-seeking,
volunteering, and making a plan for cancer screening. In their study, Ahadzedah and
Sharif (2018) found that changes in quality of life associated with uncertainty were
significantly moderated by breast cancer patients’ active emotional coping styles. Similar
benefits of active coping were found by Guan et al. (2020) among prostate cancer
survivors and found benefits from assessing coping strategies in men with prostate
cancer. This supports the need for including a discussion of coping during genetic
counseling.
Many of the participants in our study were satisfied with their cancer-screening
regimen. This is contrary to Makhnoon, Shirts, et al. (2019), who reported that some
participants wanted more screening, but aligns with Tsai et al. (2020), where participants
thought their medical care was sufficient. Planning for screening was a common method
of coping and seemed to provide a sense of control over cancer risks, which is also noted
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in Solomon et al. (2017). In this study, some participants wanted to have risk-reduction
surgery, and others were not interested in pursuing surgery without a pathogenic variant.
The interest in prophylactic surgery was in individuals with personal histories of cancer or
cancer in close relatives. Although their concern was compounded by the VUS, it was not
solely based on it. Culver et al. (2013) found that all individuals in the study who had a
bilateral salpingoophorectomy met surgical criteria based on personal or family history of
cancer. This supports the need to better inform individuals of the applicable cancerscreening guidelines, including the recommendation to base screening and risk reduction
on cancer history and not the VUS.
The Experience of Individuals With a VUS Result for Hereditary Cancer
Susceptibility in Communication With Healthcare Professionals
Communication with HCPs plays an important role in both the understanding of
and reaction to a VUS result. Participants who were given clear recommendations and
explanations appeared to be happier with their healthcare and less worried about the
VUS being pathogenic. Participants who didn’t feel their provider was knowledgeable
were less likely to trust their recommendations. Aspects of clear provider communication
included pretest genetic counseling and clear communication. Participants stated that
they appreciated availability of the genetic counselor for questions or follow-up.
Some participants were not interested in general screening guidelines and wanted
to pursue higher risk screening as they felt more in control by doing so. This
disagreement with the recommendations of the HCP may lead to frustration and possibly
searching for a new provider. Makhnoon, Shirts et al. (2019) also noted that participants
were frustrated when they felt their concerns were dismissed. J. G. Hamilton et al. (2019)
found that having a VUS was related to a decreased satisfaction with care. Most of the
individuals in this study understood that having a VUS didn’t change management of their
follow-up healthcare.
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Non-genetics providers, including both primary care and specialists, have been
shown to have an incomplete knowledge of genetic testing and its implications. This is
visible to patients when communicating with them about any aspect of genetic testing,
and this lack of knowledge is especially true when considering communication about a
VUS. Training HCPs is therefore a key component of improving the communication with
patients who have a VUS. Previous studies of provider preferences for continuing
medical education modalities showed interests in workshops, lecture series or rounds,
and self-paced learning (Veilleux et al., 2020).
Participants in our study who saw a genetic counselor were particularly pleased
with their knowledge and their confidence in communicating that knowledge. Peterson
(2018) found that patients are more satisfied with genetic counselors than a PCP, and
that longer clinical visits were also more satisfactory. Our data supports this, as several
participants noted that PCPs seemed rushed or lacking genetics knowledge. The
literature supports the benefits of counseling by a provider trained in genetics, especially
a genetic counselor (Conway et al., 2020; Senter & Hatfield, 2016).
Racial bias had detrimental effects on communication with HCPs. Our study
showed that not listening or providing treatment regimen choices was experienced by a
woman of color from a white provider. When she changed to a provider who was also a
person of color, she felt she was listened to and given more options. In the literature,
implicit racial bias from genetic counselors was associated with less individualized
information (Lowe et al., 2020). Chapman-Davis et al. (2021) found that 39.1% nonHispanic Blacks met one or more criteria for genetic testing prior to their own cancer
diagnosis. They also noted that non-Hispanic Blacks and Asians had higher rates of VUS
compared to non-Hispanic whites and Hispanics (Chapman-Davis et al., 2021). This
signals that racial biases still influence who gets genetic testing and the
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recommendations they receive. Further training for HCPs in recognizing and resolving
these disparities is crucial, as is training a more diverse healthcare workforce.
In our study we did not find negative emotional outcomes from telehealth or
telephone encounters; however, individuals were more likely to mention how they were
given the results if it was an actual scheduled visit versus just a phone call and/or a
results letter. It was noted in the literature that non-in-person results delivery was
associated with negative outcomes (Giri et al., 2018; Makhnoon, Garrett, et al., 2019).
Prioritizing in-person or face-to-face discussions (such as video calls) was recommended
by (Veilleux et al., 2020). Participants also appreciated summary letters and letters they
could share with their family, which is supported by the findings of (Makhnoon et al.,
2021). Ensuring that the patient receives a summary letter explaining the results,
implications, and recommendations is one way of supporting clear communication
between patient and providers. This not only gives them something as a memory aid, but
they can also share the letter with their healthcare team when seeking cancer screenings.
The Experience of Individuals With a VUS Result for Hereditary Cancer
Susceptibility in Communication With Family Members
In this study, most of the participants told their genetic test results to their family
members. Participants who hadn’t shared their test results with family members noted
that they didn’t have any close relatives to share them with. This is consistent with J. G.
Hamilton (2019), Solomon et al. (2017), and Cypowj et al. (2008), who also found that
most participants would share their results with family. Li et al. (2018) also noted a
willingness to share based on closeness and a feeling of duty, as did Young et al. (2019).
A major barrier identified was when individuals lived in other countries where
genetic testing was not readily available. They may have told some relatives about the
VUS and family history, but in some cases thought that doing so would be pointless. Li et
al. (2018) also found that sharing had not occurred if the information was not seen as
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useful. This indicates a need to establish the importance of the information for family
members and, if appropriate, to assist in making connections for genetic testing in other
countries. In some cases, a barrier was the perception that a family member couldn’t
understand or handle the information. This is similar to what Makhnoon, Shirts, et al.
(2019) found in their study, where individuals did not share the information when they
thought it was too hard to explain or could cause more harm than good.
When individuals did share the information, it seemed to be supported by
emotional closeness. Some participants noted they are very open with their family about
their health. One participant had their sibling attend the genetic counseling visits, and
others had their partners participate in the process. In the literature, Young et al. (2019)
found that the family culture influenced communication. Additionally, family presence
during genetic counseling was studied by Gilbar and Barney (2018), and while shown to
mostly provide emotional and informational support, there were some situations in which
the family member would try to exert influence on the decision-making process or might
be participating for their own benefit. Family communication can be influenced by
providers (Young et al., 2019), and the presence of family can be encouraged as long as
the patient’s autonomy is respected. However, Rodriguez et al. (2016) did not find that
closeness influenced communication in their study of sharing family cancer history
information, but instead found that cohesion was a more important factor.
In some cases, the participants shared information on the family history and the
VUS with the expectation or hope that their relatives would seek testing or cancer
screenings. Especially in the case where children were young adults, participants stated
they hoped to influence their health behaviors and get them to screen early and often.
This is consistent with Cypowj et al. (2008), who noted a belief that the family members
also needed tested or increased surveillance resulted in sharing the information with
family members. Young et al. (2019) also found that a feeling of responsibility existed to
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protect family, especially children. However, we did not find that parental guilt impeded
communication as they did. This indicates that parents may need particular support in
communicating with their children, as well as assistance with coping with the fear of
having given their child a risk of cancer.
The participant’s family was often noted to be a source of emotional support. This
is consistent with Ahadzedeh and Sharif’s (2018) study of breast cancer patients, where
familial support helped patients cope with the burden of cancer. Our study found that
partners, siblings, and adult children assisted participants in researching information
about their VUS and developing a plan for medical care. We did not find the alienation of
male partners of women undergoing testing that Peterson et al. (2018) noted in their
study. Individuals could be encouraged to seek this support as a means of coping with
the VUS.
Relevant Existing Theories
Uncertainty Theories
Mishel’s Uncertainty in Illness theory (UIT) is a framework that describes how
uncertainty affects psychosocial outcomes (Zhang et al., 2017). This theory has been
applied to individuals with a variety of diagnoses, from cancer to multiple sclerosis. The
framework describes how uncertainty can be appraised as either a threat, leading to
negative emotions, or an opportunity, which leads to action and better coping. The
antecedents of this appraisal are the “stimuli frame,” or how different or incongruent the
symptoms of the illness are; and the “structure providers,” which are credible authority,
support, and education (Zhang et al., 2017). Although the UIT and our model have a lot in
common, the one main difference is that individuals with a VUS do not have symptoms.
The VUS is not an illness; it will not likely even cause an illness. It also does not account
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for the unique communication needs of individuals with a VUS. Therefore, we cannot
apply the UIT in this population.
Brasher’s Uncertainty Management Theory (UMT) was based on the UIT (Rains
& Tukachinsky, 2015). The major difference is that uncertainty can stem from a variety of
sources, not just illness-related symptoms, which is likely why it has been used in
asymptomatic genetic testing. In this model, appraisal is dichotomous as either hope or
danger. Appraisal can be predicted by how incongruous the level of certainty is with the
individual’s personal goals (Rains & Tukachinsky, 2015). This model incorporates a
reassessment of uncertainty levels after information is obtained (Rauscher et al., 2018).
The UMT is useful in understanding the appraisal of uncertainty, but it does not meet our
needs for describing the entire experience of a VUS.
Communication Theory
Brown and Levinson’s Politeness Theory is a model of communication that helps
to explain why providers who are not knowledgeable about a VUS may try to appear as if
they are and may end up making incorrect recommendations (Bylund et al., 2012). In this
model, the provider is trying to present a “good face” to the patient and be accepted.
Meanwhile, the patient may be trying to maintain their autonomy in decision-making,
which Brown and Levinson describe as a “negative face.” While this theory is important to
consider in describing pieces of provider communication, it is by no means
comprehensive enough to understand the whole process of communication.
Feldman-Stewart’s proposed model of patient-provider communication is a
comprehensive description of the process. It includes the interaction between patient and
provider, the environment in which the communication takes place, the goals of both
patient and provider, and external influences on each (Feldman-Stewart et al., 2005).
This model is useful in describing how outside factors, such as lack of knowledge, could
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influence communication for each party, as well as how the goals of each may not align.
If the goal of our model were focused solely on communication, this would be an
excellent model.
Social network theory is one way of looking at family communication. The network
is a series of nodes and connections, where the nodes are people. The outcomes are not
due simply to the individual people but are due to the attributes of the connections
between them (Koehly et al., 2003; Wright, 2016). This theory is being used more
frequently to understand family communication about cancer risks.
Proposed Theoretical Model
This study employed the grounded theory design that aims to expand upon our
understanding of living with a VUS result for hereditary cancer susceptibility by identifying
the key elements of this experience and describing the relationships of those elements.
The proposed theory (see Figure 4.1) developed from the results describes how
individuals live with a VUS result that carries a high level of uncertainty; how individuals
make meaning of it depends on contextual factors, including their personal
characteristics, coping mechanisms, and cancer history. Key elements in this experience
are communicating with family, communication with HCPs, and making decisions on
healthcare. The needs of individuals with a VUS include knowledgeable and trustworthy
providers, open lines of communication, and support for emotional needs.
Implications
Clinical Practice
Multigene panel tests (MGPT) are increasingly used for individuals with personal
or family cancer histories in order to identify those who have a genetic risk for disease.
With the expansion of some cancer panels to include 80 or more genes, the odds of
getting a VUS are close to 50%. Given this increase in the number of individuals
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undergoing genetic testing for hereditary cancer risks, and the chance of getting a VUS, it
is critical that providers understand this result and are able to support individuals with a
VUS result through this process, including helping individuals understand the
implications, supporting their emotional needs, and supporting communication with
family.
Genetics and hereditary disease risks play an integral part in providing holistic
nursing care. Although the focus of precision health is often the identification of
pathogenic variants that cause a predisposition to certain diseases, an often-overlooked
aspect is supporting the individuals and their families as they go through the testing
process and beyond. As demonstrated by the lack of literature identified in our scoping
review, there is even less knowledge about how to support individuals with a VUS. This
study has identified several factors that impact the experience of a VUS, including
personality characteristics, coping mechanisms, and communication with HCPs.
Therefore, as providers work with individuals who have a VUS, they should help the
person identify how they best cope with the uncertainty, and not rely on one-size-fits-all
solutions.
Genetic counseling focuses not only on the transmission of information about the
genetic test being performed, but also on identifying how the individual and their family
will be impacted by different possible results. This includes a discussion of the testing, its
possible results, and their implication for individuals tested and their families. As a VUS
result is becoming common among tested individuals, the genetic counseling process
should include a possible VUS result, its implications, coping strategies, and how the
individual responds to uncertainty. All providers need to understand the nature of having
a VUS result and how to improve coping strategies and reduce the stress around
uncertainty for the patients and their family members. Personalized health must be about
caring for the whole individual, not just identifying their genetic risk.
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In order to ensure clear communication and avoid confusion, providers who are
working with those who have a VUS result for cancer must have a basic understanding
and knowledge in genetic testing and implications of the possible test results, and
therefore training must be provided. For practicing clinicians, this can be accomplished
through specialty-specific professional development. In order to increase the knowledge
of new clinicians (including nurses and physicians), genetics training should be
incorporated into the curriculum, with a particular focus on helping individuals through the
testing process and understanding their results.
Research
Several areas for further research have been identified. First, more research is
needed regarding the effects of personality and personal coping strategies on the
experiences of having genetic testing, particularly focused on the uncertainty of having a
VUS. The results of this study show the importance of individual characteristics on the
reactions and experiences of receiving a VUS, which can be used to support those with a
VUS result and their families. The literature so far discusses emotions as an outcome
only, and does not look at coping, personality influences, or emotional state during
testing. Future studies should focus on developing an understanding of how individual
context influences the experiences of a VUS.
Although we did not specifically aim to understand experience based on delivery
method, outcomes in the literature differed based on delivery methods (in-person vs.
telephone or telehealth). Given the increasing use of telehealth since the start of the
pandemic, more research is needed into possible differences in outcomes, as well as
methods of mitigating those potential differences. Future studies could also focus on what
delivery methods are best suited for pre- or posttest counseling.
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Finally, more testing of the model developed in this study is needed to fully
capture the experiences and areas to improve during and beyond the testing process for
those with a VUS result. More information regarding styles of HCP communication and
measurements of provider knowledge should be collected to better understand the
barriers in this area. Similarly, future studies should focus on gathering more information
on personal characteristics with regard to coping and personality traits. Finally,
prospective studies should be conducted to gather this information as individuals
progress through the genetic testing process, which will alleviate some of the issues with
recall bias that exist in a retrospective study.
Limitations
The small convenience sample used in this study, while of an acceptable size for
a qualitative study, limits generalizability of the results. Much of the sample had a higher
level of education than is the average for the United States, which may have led to a
stronger motivation to participate in research. The sample demographics did not also
include any participants who stated that they were nonbinary or Hispanic/Latino.
Recruitment and data collection for this study were conducted via remote methods
during the ongoing pandemic. This did allow for a nationwide sample. However, it may
have excluded individuals who did not have access to the recruitment messages or didn’t
feel comfortable with the technology used to participate. Remote interviews may also
cause a change in the style or interpretation of nonverbal communication, especially
when conducting audio-only interviews.
This study was retrospective in nature. The varying time periods since results
disclosure may have led to differences in recall of the genetic testing process.

92

Conclusion
The purpose of this grounded theory study was to describe the experiences of
having a VUS, from the viewpoint of the individuals with this result. Additional focus was
given to communication with HCPs and family members. In the literature review, we
found that the limited available studies showed that a high level of uncertainty and
misunderstanding existed about the VUS result for cancer. Communication with HCPs
was often described as frustrating and, although the studies show that individuals
communicated with their family, there is no description of how the communication
occurred or what they communicated. Our qualitative findings supported the themes of
personal characteristics, emotions, communication with family, and communication with
HCPs. These themes are seen across all the time categories in this study, which were
pretest, testing, posttest, and long term. The theoretical model developed from this study
describes a contextualized experience of having a VUS, with the context influencing the
processes of decision-making, communicating with HCPs, and communicating with family
members. The needs of individuals with a VUS described in this study include
knowledgeable and trustworthy providers, support of emotional needs, and open lines of
communication.
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USA

Chern et al.,
2019

France,
Germany,
Spain

Reference
and
country
Bredart et
al. 2019

To compare
the cancer risk
management
decisions of
patients with

To evaluate
changes in
psychosocial
problems
before and
after genetic
testing and
prospectively
compare
between
genetic test
results
in women
tested for
breast or
ovarian cancer
genetic

Aim

VUS or
negative
BRCA1/2

Test result
of the
population
Any result on
BRCA 1/2

646 (86%) were
assessed after
the initial genetic
consultation, of
which 460 (61%)
were assessed
again after
receiving the
test result
Women 18-90
years who had
BRCA1/2 test;
participants with
a VUS were

752 women
eligible for
breast cancer
risk testing,
unaffected or
affected with a
non-metastatic
BC.

Population

Risk reducing
breast surgery and
RRBSO uptake,
Surgical pathology

Assessment: pretest and 2 months
after the genetic
test

Genetic test
results,
Clinical data
PAHC measuring
personal, family
and social issues,
emotions, familial
and personal
cancer worry, and
children-related
issues

Assessment and
measurements

Sample characteristics and main findings of the articles included in the scoping review.

LITERATURE REVIEW TABLE

APPENDIX A

Chart review
study.

Observational
prospective
study.

Methods

Women with a VUS result
were more racially diverse,
and less likely to be
privately insured.
There was no significant

The receipt of psychological
help after testing was
associated with higher
problems in the ‘emotions’
domain.

Individuals with a VUS
result decreased more in
psychosocial problems
related to hereditary
predisposition and
familial/social issues after
receiving test result.

Results
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USA

Culver et
al.,
2013

USA

Conley et
al., 2020

To compare
surgical
decisions, risk
perceptions,
cancer
distress, and
opinions about
GT process in
those with UN
vs VUS

To analyze
patterns of
results
disclosure in
young Black
breast cancer
survivors

VUS to those
of patients with
definitive
negative
genetic testing
results

VUS or UN
in BRCA1/2

Any result
from the
study
provided
BRCA1/2
test

785 women with
a personal or
family history of
breast cancer,
enrolled in City
of Hope registry
from 1997-2010

matched by age
and date of test
to a negative
test result; 99
women with a
VUS test result
were included
149 Black
women living in
Florida,
diagnosed with
invasive breast
cancer before
age 50

Assessment: 2
year follow up
survey with
questions
regarding recall of
surgery and cancer
risks, cancer
concerns, utility of
GC; medical
records review

Surgical decisions,
Risk perception,
Cancer distress,
perception of
GC/GT.

Disclosure of
results to family 12
months after
having genetic
testing

Case control
design with
pre- and posttest
assessments.

Quantitative,
crosssectional
study.

Disclosure to female
relatives was higher, except
for those with a PV, who
were less likely to disclose
to daughters.
Other results did not predict
disclosure.
Concern for family was
most common reason for
disclosure.
There was no significant
difference in surgical
decisions for VUS vs
negative result.
All BSO in VUS group met
guidelines.
BC risk recall was 75% for
both groups.
OC risk recall was 56%.
15% with VUS and 10%
with UN believed they were
high risk.
The VUS group reported
significant change in
concerning thoughts with
92% reporting a decrease

difference in personal
history and in rate of
RRBSO uptake.

96

Spain

Esteban et
al., 2018

USA

Elsayegh et
al.,
2018

To evaluate
predictors of
CPM in
individuals
who had
MGPTand
determine
whether
predictors of
CPM differ by
gene or result
type
To seek
patient
opinions and
preferences
regarding
results
disclosure and
to analyze the
psychological
impact of
multigene and
cancer testing
Any results
on the 25
gene panel

Any PV or
VUS on
MGPT

187 participants
diagnosed with
cancer from a
parent study,
who either met
NCCN criteria
for HBOC or
Bethesda criteria
for LS.

314 women from
a MD Anderson
registry with
breast cancer
who had MGPT
from 2014-2017

Assessments:
Questionnaires

Psychological
impacts of testing;
patient's opinion
and preference for
what is disclosed of
the genetic test
result;
MICRA, IES, CWS;
Medical information
and GT genetic test
results;

CPM uptake

regarding surgery
to determine
appropriateness of
surgery

A comparison
of two cohorts
using
quantitative
measurement
s at 3 time
points.

Analysis of
existing
registry data.

CWS scores did not change
over time and it did not
differ depending on GT
result.
IES did not differ depending
on results and there's no
statistically significant longterm change.
Patients with a PV had
higher distress then
patients with negative or
VUS result.
There was a tendency
among patients with high

in frequency.
A majority of both groups
saw GC as helpful.
All of the VUS patients who
were dissatisfied with GC
stated that it didn't provide
new knowledge.
10.6% of VUS carriers
elected CPM.
PV carriers are more likely
to elect CPM than those
with a VUS.
In the VUS group receptor
status was not associated
with CPM election but age
was.
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USA

Giri et al.
2018

To understand
men's needs
regarding
genetic testing
for inherited
prostate
cancer and
evaluating
their
knowledge of
cancer risk
and personal
results

Any PV or
VUS

109/200
participants from
the GEM parent
study
A significant
difference
between
responders and
non-responders
was that 80% of
those with HCS
responded to the
survey vs 44.8%
without HCS
Assessments:
medical history,
lifestyle, risk
factors, knowledge
of prostate cancer
risk, genetic
literacy.
Participants
received post-test
survey by mail.

Baseline
assessment
followed by GC
(either in person or
by telehealth) and
genetic testing,

were selfadministered after
the pre-test visit,
and 1 week, 3
months and 12
months after
results disclosure
Knowledge of
cancer risk and
genetics,
Understanding of
personal test
results
Quantitative
surveys using
a pre- and
post-test
design.

101 participants responded
that they definitely
understood their test
results,
88 of which responded
correctly regarding the test
results and
13 responded incorrectly
answering that they carry a
mutation when they did not.
12/13 who responded
incorrectly had at least 1
VUS.
Having a VUS result was
significantly associated with
reporting incorrect test
results.
Phone or telehealth
disclosure were also
associated with
misunderstanding of results

penetrance PV to report
that they understood their
options better.
Most patients wished to be
disclosed VUS and
moderate penetrance PV.
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USA

Hamilton et
al., 2019

To
characterize
the genetic
testing
experiences,
medical
management,
and
psychosocial
adaptation of
individuals
living with
CDH1 variants

CDH1 PV or
VUS

57 individuals
identified
through the
PROMPT
registry with a
CDH1 PV or
VUS

Assessment:
Survey completed
online 0-4 years
after results
disclosure

Understanding of
result,
Nomenclature of
variant,
Personal and
family history,
Impact of MGPT,
Adapted Carolina
Genomic
Knowledge scale,
Adapted NCI risk
measure, Decision
Regret Scale;
Emotional distressMICRA and Worry
about
discrimination
question,
QOL,
family
communication

Crosssectional
design using
a quantitative
online survey.

8 cases had conflicting lab
classifications; 1 discordant
LP/P vs VUS and 7 VUS vs
LB/B.
12/56 self-report discordant
with 3 participants reporting
PV and actual result VUS
45.6% recalled pretest
information about the
possibility of a VUS.
Those with VUS reported
significantly lower CDH1
knowledge and less
satisfaction with HCP
knowledge.
Both VUS and LP/P groups
reported cancer risks at
scale midpoints.
Most had shared result with
family.
VUS group more likely to be
concerned about scaring
family.
VUS less likely to have
family interested in testing.
69.2% of VUS had breast
MRI.
92% of VUS had
mammogram at least
yearly.
6% of VUS group had
upper endoscopy at least
yearly.
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USA

Miron et al.,
2000

Singapore

Li et al.,
2018

To present the
spectrum of
BRCA 1/2
mutations and
the reactions
of women after
results
disclosure

To explore
facilitators and
barriers to
sharing
information
with family

BRCA 1/2
VUS or PV

Any BRCA
1/2 result

In the main
study, testing
was offered to
221 probands
and 110
relatives.
In this study,
213 probands
accepted,
relatives were
incomplete at
time of
publication

24 women in
Singapore who
had GT for
HBOC

Assessments:
Baseline survey
attitudes,
knowledge about
cancer genetics,
GT, and risk
perception.
Follow up surveys
after test decision,
results disclosure,
and posttest GC

Randomly
assigned 2 forms of
written materials
about HBOC and
GT. All were
offered free GC
prior to decision to
test.

Family
communication
assessed by semi
structured
interviews

Quantitative
surveys
completed
pre- and postfree GC and
testing.

Qualitative
grounded
theory design
with inductive
thematic
analysis.

Willingness to share is
based on closeness and
feeling the duty to inform.
If the participant thought the
family member could
handle genetic information,
they were willing to share.
Individuals who shared
wanted to influence
outcomes for family.
Some did not share
because they wanted to
avoid misunderstanding
and false alarm.
Subject’s self-estimate and
the calculated estimates
differed significantly from
each other.
15/25 who were interested
in RRM before GC and
testing and received a
negative test result were no
longer interested in surgery
3/4 VUS also changed
minds on RRM.
BSO decisions were less
changed by test results.
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To describe
the
experiences of
individuals
who had a
VUS result on
genetic testing
for LS

Solomon et
al., 2017

USA,
Canada

USA

To assess
patient
understanding
of a VUS
identified on
MGPT and
factors that
may influence
recall, reaction
to, and
interpretation

Reuter et
al., 2019

Any VUS on
LS panel

Any VUS in
the absence
of a PV

21 females 6
males who had
testing for LS
due to a
personal or
family history of
cancer.

10 female, 1
male who had a
VUS on MGPT

Assessment: semi
structured
interviews, most
within 1 year of
results disclosure

Assessment: semi
structured interview
in person or via
phone 5-13 months
after results
disclosure
Recall, uncertainty,
appraisals,
expectation of
reclassification

that included
specific questions
on risk estimates,
interest in
prophylactic
surgery
Factual recall,
perceived
significance,
response to result,
expectations and
motivations for
testing

Codes were
developed
based on
concepts of
interest and
the interview
guide, and
data were
coded in an
iterative

A qualitative
study

Qualitative
study,
analysis used
an iterative
approach with
both inductive
and deductive
coding.

2 participants could not
recall having a VUS.
There was variation in
describing results.
Participants generally
understood that a VUS
doesn't impact medical
management.
Some did not understand
that a genetic etiology was
still possible. Emotional
responses varied.
Most do not report frequent
thoughts about VUS
23 recalled having a VUS.
27 connected their result to
their history.
13 did not know about the
possibility of a VUS pretest.
Responses ranged from
relief to shock. 23
conceptualized VUS as
uncertain.
10 self identified as having
LS.
7 said they did not have LS.
17 appraised VUS as a
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France

Cypowyj et
al., 2009

To describe
subjective
understanding
of BRCA1/2
VUS and
explore
communication
of results to
family

BRCA1/2
VUS

30 women being
followed by the
clinic in France

Data collected from
geneticist regarding

Assessment: Two
years after results
disclosure

CESD and IES;
CancerGene
probability
calculated;
Researcherdeveloped
questionnaire on
transmission of info
to families and risk
perception

Qualitative
data was
analyzed
using
thematic
analysis.

A mixed
method,
crosssectional
study

process.

threat, 17 appraised as an
opportunity. Participants
often repeated what
providers told them.
Mobilizing was most
common coping strategies
17 reported having a plan
for screening.
15 communicated with
family.
6 sought information.
14 expected
reclassification.
There was a perceived
benefit from following a
surveillance and
management plan
7 women recalled a PV, 9
recalled a negative result,
14 were uncertain.
76% had communicated
test results to their family
within the 2 years after the
test.
Individuals in the uncertain
group found it difficult to
explain the information to
families because it was
unclear. Participants also
included comments about
what their physician told
them.
Most of the women who
thought they were positive
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USA

Makhnoon,
Garrett, et
al., 2019

USA

Garcia et
al., 2014

To describe
decision
making and
follow up in
women with
VUS vs PV
To explore the
experiences of
patients with a
VUS result
who were
seeking
reclassification
VUS

BRCA 1/2
PV or VUS

374 women
followed by
Kaiser
Permanente
after genetic
testing.
25 female and 1
male eligible for
screening based
on family history

Assessment: Semistructured phone
interviews

Motivations for
reclassification,
VUS
interpretations,
understanding of
screening
recommendations,
emotional
responses

Rates of RRSO,
RRM, surveillance,
time to reclassify

medical history and
risk assessment

A qualitative
study. Semistructured
interviews
were
analyzed
using
inductive
thematic
analysis.

Chart review.

told their family because
they thought they would
need screening.
VUS group had lower rates
of RRM RRSO than PV
group
Rates of surveillance were
low for both groups and
dropped every year.
Individuals were motivated
by history and prevention.
Uncertain VUS
interpretations understood
but lacked guidance on how
to move forward.
Some individuals wanted
more screening and family
testing; most
misunderstood
management
recommendations. Negative
affects occurred after
disclosure. Individuals
expressed frustration with
providers and felt their
worries were dismissed.
Some felt relief or
indifferent about the VUS.
A majority were more
concerned for their family.
Post-test counseling via
telephone described as
“imperfect”.
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Canada

Richter et
al., 2013

USA

Makhnoon,
Shirts, &
Bowen,
2019

To compare
individuals with
different types
of results
regarding
comprehensio
n, perceived
risk, cancer
worry, and
surveillance/
risk reduction;
also, to
determine

To understand
why some
individuals
have difficulty
after a VUS
result.

Any BRCA
1/2 result

VUS in
genes
associated
with breast,
colorectal,
uterine, or
prostate
cancer.

144 women who
had been seen
at a breast
cancer clinic

11 women
identified
through a clinic
registry

GCs were also

Assessment:
mailed surveys

Recall and
significance, risk
perception, cancer
specific worry,
adoption of
surveillance and
risk reduction,
Trask Worry Score

Assessment: Semistructured inperson or phone
interviews

Emotions,
understanding,
views of process

A
quantitative,
crosssectional
design with
survey data
collected from
individuals
who had
genetic
testing, GCs,
and

Hybrid
deductive
content
analysis of
semistructured
interviews
using the
framework of
Han’s
Taxonomy of
Uncertainty.

A qualitative
study.

Uncertainty regarding future
pathogenicity of VUS and
prognostic concerns.
Ambiguity related to
complexity of information.
Participants were aware of
environmental etiology of
cancer.
They did not want to share
with family if it causes more
harm than benefit.
Participants expressed
frustration and concerns
about GT process.
Emotional outcomes were
better when providers
discussed coping strategies
for VUS prior to test.
Those who were
unprepared for VUS had
more uncertainty.
VUS group had the highest
rate of incorrect recall
(36%).
VUS and negative groups
both reported decreased
perceived risk.
VUS had intermediate
levels of worry.
GC would make
recommendations based on
histories for those with VUS
MDs said they would refer a
family of a proband with a
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The
Netherlands

Vos et al.,
2008

To examine
possible
differences
between recall
and
interpretation
in individuals
with a VUS
using the
distorted
perception
hypothesis

practices and
perceptions of
VUS among
clinicians

VUS in
BRCA1/2

24 women with
breast and/or
ovarian cancer
who had
received their
results from one
of two Dutch
cancer clinics
Assessment:
Likert style
questions and
open-ended
interview
questions. Data
about genetic
counseling was
collected from GC
summary letter.

asked about
practice patterns,
counselee worry,
and
comprehension.
Physicians were
asked about
practice patterns
Understanding,
perception of GC,
expectations of a
VUS, uncertainty
about the possible
genetic cause of
family cancer
history assessed
by interviews.
A mixedmethod study
which was
part of a
larger study
where GT
was offered to
unaffected
relatives of
probands with
a VUS.

physicians.

67% recalled the VUS as
uninformative.
79% interpreted VUS as
pathogenic;
21% interpreted it as
uninformative.
The disclosure of the VIS
was described as neutral.
The mean life change score
was low.
Large life changes were
mentioned in the interview.
7 had a mastectomy due to
VUS.
No difference in surgery
choices between those who
recalled result as PV or
VUS.

VUS for testing.

APPENDIX B
FLYER

HAVE YOU HAD AN
UNCERTAIN GENETIC TEST
RESULT FOR HEREDITARY
CANCER RISKS?
We are conducting a study of individuals with a Variant of Uncertain
Significance (VUS) in order to learn more about their experiences and needs
in understanding the test result for themselves and their family members.
Additionally, we are trying to understand the process of communication with
their first-degree relatives and healthcare providers about genetic risk and
risk management. Participation is expected to take 80 minutes in total.
If you are interested in learning more
about this study, please follow this
link: <link to qualtrics> or scan the
QR code below:

You may be eligible participate
in this study if you:
- Are over age 18
- Are able to speak English
-Can participate in an interview
via telephone or video chat
- Had a variant of uncertain
significance (VUS) on a genetic
test for hereditary cancer risks

Placeholder

Contact the study team:
Danielle Gould, PhD Candidate
Daniellegoul@umass.edu
413-545-9922
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APPENDIX C
RECRUITMENT EMAIL

Email messaging:
Dear <name of community contact>,
I am currently seeking participants for my dissertation study at The University of Massachusetts
Amherst, titled “The Experiences and Needs of Individuals With a Variant of Uncertain
Significance (VUS) on Genetic Tests for Hereditary Cancer Syndromes: A Grounded Theory
Study” (IRB protocol 2477). This study seeks to further our understanding of the experiences
and needs of individuals with a certain genetic test result, called a “VUS”, on genetic testing for
hereditary cancer risks.
To be eligible, participants must:
- Be over age 18
- Be able to speak English and connect via telephone or video chat
- Had a Variant of Uncertain Significance (VUS) on a genetic test for hereditary cancer
susceptibility
- Has access to or recall of the result nomenclature
Participation is expected to take 80 minutes in total. If any members of your community are
interested, they can find more information by following this link: <qualtrics link to consent and
survey>. Any questions can be directed to me via email daniellegoul@umass.edu.
Thank you for your time and assistance to disseminate this information
Sincerely,
Danielle Gould MSN, APRN, FNP-C
PhD Candidate
University of Massachusetts, Amherst
College of Nursing
Social media (Twitter, Facebook, Instagram, discussion boards/forums):
I am currently seeking participants for my dissertation study at The University of Massachusetts
Amherst (IRB protocol 2477), which seeks to further our understanding of the experiences and
needs of individuals with a certain genetic test result, called a “VUS”, on genetic testing for
hereditary cancer risks. Participation is expected to take 80 minutes in total. For more
information and eligibility criteria, please follow this link <qualtrics link to consent and survey>.
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APPENDIX D
IRB DETERMINATION LETTER

Mass Venture Center
100 Venture Way, Suite 116
Hadley, MA 01035
Telephone: 413-545-3428

LETTER OF EXEMPT DETERMINATION
Date: December 4, 2020
To: Professor Memnun Seven and Danielle Gould, College of Nursing
From: Professor Lynnette Leidy Sievert, Chair, University of Massachusetts Amherst IRB
Protocol Title: The Experiences and Needs of Individuals With a Variant of Uncertain Significance (VUS) on
Genetic Tests for Hereditary Cancer Syndromes: A Grounded Theory Study
Protocol ID: 2477
Review Type: EXEMPT -NEW
Category: 2
Review Date: 12/04/2020
No Continuing Review Required
UM Award #:

The Human Research Protection Office (HRPO) has reviewed the above named submission and has
determined it to be EXEMPT from the federal regulations that govern human subject research (45 CFR 46.104)
Note: This determination applies only to the activities described in this submission. All changes to the
submission (e.g. protocol, recruitment materials, consent form, additional personnel), must be reviewed by
HRPO prior to implementation.
A project determined as EXEMPT, must still be conducted in accordance with the ethical principles outlined in
the Belmont Report: respect for persons, beneficence, and justice. Researchers must also comply with all
applicable federal, state and local regulations as well as UMass Amherst Policies and procedures which may
include obtaining approval of your activities from other institutions or entities. All personnel must complete
CITI training.
Consent forms and study materials (e.g., questionnaires, letters, advertisements, flyers, scripts, etc.) - Only use
the consent form and study materials that were reviewed by the HRPO.
Final Reports - Notify the IRB when your study is complete by submitting a Close Request Form in the
electronic protocol system.
Serious Adverse Events and Unanticipated problems involving risks to participants or others - All such events
must be reported in the electronic system as soon as possible, but no later than five (5) working days.
Annual Check In - HRPO will conduct an annual check in to determine the study status.
Please contact the Human Research Protection Office if you have any further questions. Best wishes for a
successful project.
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APPENDIX E
CONSENT FORM

Consent Form for Participation in a Research Study
University of Massachusetts Amherst

Researcher(s): Danielle Gould MSN, APRN, FNP-C, PhD Candidate
Memnun Seven PhD, RN, Assistant Professor and Faculty Sponsor
Study Title: The Experiences and Needs of Individuals With a Variant of Uncertain Significance
(VUS) on Genetic Tests for Hereditary Cancer Syndromes: A Grounded Theory Study

1. WHAT IS THIS FORM?
This form is called a Consent Form. It will give you information about the study so you can make an
informed decision about participation in this research. We encourage you to take some time to think this
over and ask questions now and at any other time. If you decide to participate, you will be asked to sign
this form and you will be given a copy for your records.
2. WHAT ARE SOME OF THE IMPORTANT ASPECTS OF THIS RESEARCH STUDY THAT I
SHOULD BE AWARE OF?
1) Consent is being sought for research and participation is voluntary.
2) The purpose of this research is to further our understanding of the experiences of individuals who
have had a Variant of Uncertain Significance, or VUS, on genetic testing for hereditary cancer
susceptibility.
3) Your participation will involve completing an online questionnaire which will take 15-20 minutes
and an interview via telephone or video call, which will take approximately 45-60 minutes.
4) If you are not comfortable with being recorded, you should not participate in this study.
5) There are minimal risks expected from participating in this study. However, there is a risk of
psychological distress or negative emotions due to the discussion of experiences related to genetic
testing.
6) There are no direct benefits to you. However, by participating in this research you will be
contributing to science and the improvement of health care.
3. WHY ARE WE DOING THIS RESEARCH STUDY?
We are conducting this research study to explore the experiences and needs of individuals who had a
variant of uncertain significance result (VUS) in genetic testing for hereditary cancer susceptibility. We
plan to focus specifically on their experiences and needs in the interpretation of the test result for
themselves and their family members. We also plan to examine the process of communication with
healthcare providers and their first-degree relatives about genetic risk and risk management.
4. WHO CAN PARTICIPATE IN THIS RESEARCH STUDY?
You can participate in this study if you:
- Are over age 18
- Able to speak English and connect via telephone or video chat
- Had a variant of uncertain significance (VUS) on a genetic test for hereditary cancer risks

University of Massachusetts Amherst-IRB
Protocol #: 2477
IRB Signature:
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- Have access to a copy of your test result or can recall the specific result
You cannot participate in this study if you:
-Did not have a VUS result in a cancer-related gene
-Are not able to complete the interview via phone or video call.
5. WHERE WILL THIS RESEARCH STUDY TAKE PLACE AND HOW MANY PEOPLE WILL
PARTICIPATE?
Interviews for this study will be conducted remotely via telephone or video call, therefore participants can
be in any location. We expect to enroll 40 participants.
6. WHAT WILL I BE ASKED TO DO AND HOW MUCH TIME WILL IT TAKE?
If you agree to take part in this study, you will complete an online questionnaire regarding your
demographics, family history of cancer, and scheduling preferences for the interview; this should take less
than 20 minutes. Then, you will complete an interview which will last approximately 45-60 minutes. In
total, it is expected that your participation will take less than 80 minutes in total. In each step, you can
skip any questions that you are not comfortable with. You will not be contacted after your participation is
completed.
7. WILL BEING IN THIS RESEARCH STUDY HELP ME IN ANY WAY?
You may not directly benefit from this research; however, we hope that your participation in the study
may advance our knowledge and understanding of the experiences of individuals with VUS results and
therefore improve health outcomes in this population.
8. WHAT ARE MY RISKS OF BEING IN THIS RESEARCH STUDY?
We believe there are minimal risks associated with this research study.
This is a research study that involves questions related to sensitive topics such as your feelings and coping
strategies with having a VUS test result that may cause emotional or psychological distress. You always
have the option to skip distressing questions or end the interview. As researchers, we do not provide
mental health services and we will not be following up with you after this study. However, we want to
provide every participant in this study with contact information for available clinical resources, should
you decide you need assistance at any time. Mental health resources can be found at
https://findtreatment.samhsa.gov/ or by calling 1-800-662-HELP. In a serious emergency, remember that
you can also call 911 for immediate assistance.
There is also a risk of breach of confidentiality and we have taken the steps to minimize this risk as
outlined in section 9 below.
9. HOW WILL MY PERSONAL INFORMATION BE PROTECTED?
Your privacy and confidentiality are important to us. The following procedures will be used to protect the
confidentiality of your study records. Study records will be stored only in electronic format. All electronic
files (including audio recordings, transcripts, notes, survey responses, and databases) containing
identifiable information will be password protected. Any computer hosting such files will also have
password protection to prevent access by unauthorized users. Only the members of the research staff will
have access to the passwords. We will use secure cloud storage called Box.net for file sharing between
researchers, which is password protected and encrypted. A transcription service will be used, which
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employs transcription in transit and storage to keep data secure, and does not access any individual data.
At the conclusion of this study, the researchers may publish their findings. Information will be presented
in summary format and you will not be identified in any publications or presentations.
Your privacy will be protected by conducting study procedures in a private location and only allowing
authorized research team members to meet with research participants. Signed consent documents will be
stored securely and separately from the research data.

10. WILL MY INFORMATION (BIOSPECIMENS OR PRIVATE INFORMATION) BE USED FOR
RESEARCH IN THE FUTURE?
Identifiers will be removed and the de-identified information may be used for future research without
additional informed consent from you.

11. WILL I BE GIVEN ANY MONEY OR OTHER COMPENSATION FOR BEING IN THIS
RESEARCH STUDY?
You will not receive payment for participation in this research study.
12. WHO CAN I TALK TO IF I HAVE QUESTIONS?
Take as long as you like before you make a decision. We will be happy to answer any question you have
about this study. If you have further questions about this project or if you have a research-related problem,
you may contact the researcher(s), Danielle Gould and Dr. Memnun Seven by email
(daniellegoul@umass.edu, mseven@umass.edu) or telephone (413-545-9922).
If you have any questions concerning your rights as a research subject, you may contact the University of
Massachusetts Amherst Human Research Protection Office (HRPO) at (413) 545-3428 or
humansubjects@ora.umass.edu.

13. WHAT HAPPENS IF I SAY YES, BUT I CHANGE MY MIND LATER?
You do not have to be in this study if you do not want to. If you agree to be in the study, but later change
your mind, you may drop out at any time. There are no penalties or consequences of any kind if you
decide that you do not want to participate.
14. WHAT IF I AM INJURED?
The University of Massachusetts does not have a program for compensating subjects for injury or
complications related to human subjects research, but the study personnel will assist you in getting
treatment.
15. SUBJECT STATEMENT OF VOLUNTARY CONSENT
__(Check here if you agree) I understand that the interview will be either video or audio recorded and
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agree to this recording.
When signing this form I am agreeing to voluntarily enter this study. I have had a chance to read this
consent form, and it was explained to me in a language that I use. I have had the opportunity to ask
questions and have received satisfactory answers. I have been informed that I can withdraw at any time. A
copy of this signed Informed Consent Form has been given to me.
________________________
Participant Signature:

____________________
Print Name:

__________
Date:

By signing below I indicate that the participant has read and, to the best of my knowledge, understands
the details contained in this document and has been given a copy.
_________________________
Signature of Person
Obtaining Consent

____________________
Print Name:

University of Massachusetts Amherst-IRB
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__________
Date:

APPENDIX F
QUALTRICS SCREENING SURVEY
Q1 Before you officially enroll in this research study, I will be asking you to complete a
screening questionnaire. It should take you no more than 5 minutes to complete. If you
are determined to be ineligible to participate, your completed questionnaire will be
destroyed. If you are determined eligible to participate, the completed questionnaire will
become part of the study materials, and we will protect your information as confidential
and safeguard it from unauthorized disclosure. Only research personnel will have access
to the information contained in your screening questionnaire. If the screening
questionnaire indicates that you are eligible to participate, we will proceed to obtaining
your written informed consent for participation in the study.
Q2 In this study, we are looking for individuals with a Variant of Uncertain Significance
(VUS) for any cancer type in order to learn more about their experiences and needs in
understanding the test result for themselves and their family members. To determine if
you are eligible to participate, please write in or share an image of your test results with
your personal information not visible.
Q3 Enter test results here if not uploading an image:
Q4 How are you recalling these results?
o
Direct- I am looking at a copy of the results
o
From memory- this is how I remember the results
o
Other ________________________________________________
Q5 If you are eligible for the study, can you participate in the interview via video call
(Zoom, Facetime, etc) or telephone call?
o
Video call
o
Telephone call
o
Neither
Q6 Can you communicate verbally in English?
o
Yes
o
No
Q8 Where did you learn about this study?
o
PROMPT
o
Twitter
o
Facebook
o
Other ________________________________________________
Q7 How would you like to be contacted?
o
Email ________________________________________________
o
Phone ________________________________________________
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APPENDIX G
DEMOGRAPHIC SURVEY
Please read the following consent form. If you agree to participate in this study, you will
be asked to provide a signature and will then be taken to a survey which will collect
some basic information.
Please click this link to read the consent:
Click here for consent form
I understand that the interview will be either video or audio recorded and agree to this
recording.

o Yes
o No
When signing this form I am agreeing to voluntarily enter this study. I have had a chance
to read this consent form, and it was explained to me in a language that I use. I have
had the opportunity to ask questions and have received satisfactory answers. I have
been informed that I can withdraw at any time. A copy of this signed Informed Consent
Form has been given to me.

o Yes
o No
Please sign below to indicate your consent to participate in this study.
Please enter an email address where we can send you a copy of this consent:
Please fill in the following questions to the best of your ability. You may skip any
question you do not want to answer.
What was your age on your last birthday?
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What gender do you identify as?

o Male
o Female
o Transgender Male
o Transgender Female
o Other/ not listed ________________________________________________
o Prefer not to say
What was your assigned sex at birth?

o Male
o Female
o Prefer not to say
What race you identify as?

▢
▢
▢
▢
▢
▢

White
Black or African American
American Indian or Alaska Native
Asian
Native Hawaiian or Pacific Islander
Other
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Do you identify as Hispanic/Latino?

o Yes
o No
What is your highest level of education completed?

o Less than high school (elementary or junior high school)
o Did not finish high school
o High school diploma
o Some college or 2-year degree
o Bachelors/ 4-year college degree
o Graduate school/advanced degree
What is your employment status?

o Working, full time
o Working, part time
o Unemployed, looking for work
o Unemployed, not looking for work
o Disabled
o Retired
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What is your health insurance status?

o I have private health insurance
o I have insurance through the military or VA
o I have health insurance through Medicare or Medicaid
o I am covered by another country's health insurance program
o I do not have health insurance
Does your insurance cover genetic testing?

o Yes
o Not sure
o No
Do you have a personal history of cancer?

o Yes
o No
Personal history of cancer:
Age at diagnosis

Treatment

Cancer type 1:
Cancer type 2:
Cancer type 3:
Cancer type 4:
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Age at recurrence
(N/a if none)?

Family history of cancer (i.e., son, daughter, brother, sister, mother, father, grandmother,
grandfather):
Cancer type(s)
Family member kinship (i.e., son, daughter,
mother, father)
Family member kinship (i.e., son, daughter,
mother, father)
Family member kinship (i.e., son, daughter,
mother, father)
Family member kinship (i.e., son, daughter,
mother, father)
Family member kinship (i.e., son, daughter,
mother, father)
Family member kinship (i.e., son, daughter,
mother, father)
Family member kinship (i.e., son, daughter,
mother, father)
Family member kinship (i.e., son, daughter,
mother, father)
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Age at diagnosis

Contact preference

o Text (enter phone number):
o Email (enter email):
o Phone (enter phone number):
Preferred interview method

o Zoom
o Google Meet
o Skype
o Facetime
o Telephone
o Other
Is there anything else we should know?
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APPENDIX H
INTERVIEW GUIDE
How would you describe your genetic testing process?
o How did you decide?
o Who did you see?
o Were you referred?
o What prompted it?
What does it mean to you to have a VUS?
o How do you feel about having VUS result?
o How has it affected your life?
o How did it impact any decisions for treatment, screening for yourself?
o How have you coped (strategies)?
o How do you feel about your medical management?
How did you talk to your family about the GT? Did you tell them ahead of time/ after?
o How did you decide to do this?
o Who in your family know about the test result? (children, siblings, parents
etc.)
o Which information did you include in your communication?
o Are there relatives you excluded?
o How did it impact any decisions for treatment, screening among your
family members?
What do you recall being told about cancer risks?
o Who gave you this test result?
o Which information were you given?
o How did you feel after having this result?
o Do you see anyone for follow-up?
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